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RNA-binding protein and stem cell regulator, Musashi-1 (MSI1) is overexpressed in a broad 
range of human cancers and associated with poor clinical outcome.  MSI1 encourages 
tumorigenesis by promoting Notch and Wnt signaling, along with cell cycle progression.  In vitro 
and in vivo data have demonstrated that MSI1 is an attractive therapeutic target.  Accordingly, 
there is great interest in identifying and exploiting MSI1 regulating mechanisms as anti-cancer 
therapy.   
 
We successfully determined that non-coding RNA, miR-137, acts as a negative regulator of 
MSI1 by binding to the 3′UTR of MSI1 mRNA. Using numerous in vitro and in vivo studies, we 
show that miR-137 acts as a tumor suppressive miRNA in colon cancer, in part by inhibiting 
MSI1.  To understand the clinical relevance of our observations, we measured the expression of 
miR-137 and MSI1 in tissue samples from patients with rectal cancer.  miR-137 expression is 
decreased in approximately 84% of rectal tumor samples as compared to paired normal rectal 
mucosal samples. Inversely, MSI1 protein was found to be highly expressed in 79% of primary 
rectal tumors.  In addition to this study, we show preliminary data that miR-137 also negatively 
regulates Musashi-2 (MSI2).  We provide a comprehensive review on the expression of MSI1 
and MSI2 in human cancers and correlate this expression with clinical outcome and evidence for 
MSI-induced malignancy.   
 
In addition to using noncoding RNAs to inhibit MSI1, we are also identifying small molecules 
that inhibit the RNA-binding function of MSI1.  Our preliminary studies identified (−)-Gossypol, 
gossypolone and azaphilone-9 as potent MSI1 inhibitors using a fluorescence polarization-based 
screening of our in-house library of compounds.  In this study, we validated and characterized 
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the binding event between hit compounds and MSI1 RNA-binding domain 1 (RBD1) using 
nuclear magnetic resonance.  In summary, we discovered two novel means of inhibiting the 
function of MSI1 in cancer, using miR-137 and small molecule inhibitors. Our study supports the 
idea of exploiting miRNAs and small molecules as novel cancer therapy targeting the RNA-
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Chapter 1: Introduction 
 
 











Globally, cancer is an enormous burden. Cancer accounts for nearly 1 in every 7 deaths 
worldwide [1].  In 2012 alone, approximately 14 million people were newly diagnosed with 
cancer and over 8 million people died from cancer [1].  Due to population growth and aging, this 
cancer burden is growing at a disturbing rate.  In 2030, it’s predicted that approximately 21 
million people will be diagnosed with cancer and 13 million will die from the deadly disease [1]. 
 
In the United States, cancer is the second leading cause of death.  This disease is expected to earn 
the top spot as cause of death in the near future; surpassing heart disease. In 2015, 1.6 million 
people are expected to be diagnosed with cancer, nearly 4,500 people per day [1].  Over 500,000 
men and women, are expected to die from cancer this year alone, nearly 1,600 people per day 
[1]. To date, the lifetime risk for being diagnosed with cancer is 43% for men and 38% for 
women in the United States [1]. The Agency for Healthcare Research and Quality estimate that 
the direct medical cost for cancer in the United States in 2011 was 88.7 billion dollars. Overall, 
cancer is an overwhelming burden personally and financially for millions of people every year.  
 
Normal cellular function is mediated by a highly organized and complex circuit known as the 
Central Dogma of molecular biology. DNA, which contains a unique genetic code is transcribed 
into messenger RNA (mRNA) which is then translated into proteins. Being highly susceptible to 
degradation, the RNA message must be protected from powerful RNA degrading enzymes. Cells 
use sophisticated mechanisms to produce and use messenger RNA with optimal efficiency 
according to the needs of the cell.  The two major types of post-transcriptional regulators are 
RNA binding proteins (RBPs) and microRNAs (miRNAs) [2]. When RBPs and miRNAs are 




RNA binding proteins 
Typically, RNA is accompanied by RNA binding proteins.  RBPs are essential for orchestrating 
the processing, localization, lifetime and translation of RNAs (Figure 1) [3, 4]. Therefore, RBPs 
serve as protective gatekeepers of the genetic message for proper protein translation and normal 
cell homeostasis.  RNA binding proteins are major regulators of gene expression. The human 
genome contains more than 500 RBPs [5].  Some RBPs recognize the 5ʹ- cap or poly(A) tail of 
mRNA, however most RBPs recognize specific secondary structures mediated by RNA-binding 
domains [3].   
 
A large percentage of aberrant protein expression in tumors is dysregulated at the post-
transcriptional level. For example, one study found that only 21% of the transcriptome and 
proteome are positively correlated in lung adenocarcinoma [6].  The differential expression of 
RBPs is observed in most human cancers and is thought to be either a cause or consequence of 
tumorigenesis [7, 8].  RBPs regulate the expression of genes implicated in multiple cancer-
relevant processes, including proliferation, differentiation, apoptosis and cell cycle [9].  
 
The proper function of cells depend on the dynamic expression of proteins to regulate cell 
survival, homeostasis, and adaptation to stress in response to environmental signals [10].  Proper 
expression of genes is globally coordinated by post-transcriptional regulation factors, such as 
RBPs and microRNAs, termed the messenger ribonucleoprotein particle (mRNP) [11-13].  
mRNPs serve to expand the functional repertoire of humans’ unexpectedly small genome [11].  
Therefore, cells can respond to a myriad of environmental cues by mRNPs ability to exquisitely 
fine-tune the expression of genes in response to fluctuating conditions.  
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The post-transcriptional ‘RNA-operon’ theory suggests that multiple trans-acting factors 
cooperatively coordinate the processing, stability and translation of RNA, allowing cells to 
dynamically respond to environmental cues [11, 14].  Recent evidence suggest that functionally 
related mRNAs are post-transcriptionally regulated together by a large regulatory network 
including RBPs and non-coding RNAs, such as miRNAs (Figure 1) [11] .  
 
Figure 1.  Post-transcriptional regulation by RBPs and miRNAs.  RBPs and miRNAs work 
together to coordinate the splicing, transport, stability, localization and translation of mRNAs. 








miRNAs are ~22 nucleotide-long, non-protein coding RNAs that negatively regulate gene 
expression.  miRNAs function predominately by inhibiting the protein translation of target 
mRNAs by binding to the 3ʹ-untranslated region (UTR).  miRNAs are predicted to regulate over 
50% of human genes, giving them significant regulatory power over cellular homeostasis [15].  
To date, almost 1,500 evolutionarily conserved miRNAs have been identified in the human 
genome [16-18]. 
 
Most miRNAs are transcribed by specific miRNA gene loci, although 30% are located within the 
introns of protein encoding genes [19]. miRNAs are transcribed by RNA polymerase II 
generating a long hairpin structure as a primary microRNA transcript (pri-miRNA) (Figure 2). 
The primary transcript is further processed with a 5ʹ-7-methyl-guanosine (m7G) cap and a         
3ʹ-poly-adenylated tail.  The primary transcript may contain a single miRNA or clusters of 
miRNAs that are processed together [19].  The RNAse III endonuclease Drosha, cleaves the 
double-stranded stem into a ~70 nucleotide (nt) precursor miRNA (pre-miRNA). This catalytic 
event is positioned by DiGeorge syndrome critical region 8 (DGCR8) [20, 21]. The pre-miRNA 
is recognized by the exportin 5 (XPO5) and RNA-GTP complex and shuttled to the cytoplasm 
[22]. The terminal loop of the pre-miRNA is cleaved by the double-stranded RNA (dsRNA)-
specific RNase III, Dicer into ~22 nt RNA duplex with the help of the human immunodeficiency 
virus transactivation responsive RNA-binding protein 2 (TARBP2) [23, 24].  TARBP2 recruits 
an Argonaute (AGO) protein to the guide strand of the miRNA duplex [25].  The guide strand of 
the mature miRNA is assembled into the miRNA-induced silencing complex (miRISC), along 
with an Argonaute and GW182 family proteins [25]. The miRISC recognizes complementary 
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sequences of target RNA for post-transcriptional gene silencing in the processing bodies [26, 
27].  
 
miRNAs bind by base-pairing with partial or perfect complementary sites located in target 
mRNA 3ʹ-UTR [28].  A small percentage of miRNA target sites have been found in open reading 
frames (ORFs) or the 5ʹ-UTR of target mRNA [29]  Perfect complementary base-pairing 
between the miRNA and target mRNA promotes the catalytic cleavage of mRNA by AGO2 [30]. 
Out of the four AGO family protein members, only AGO2 is catalytically active [30]. When 
mRNA cleavage is not possible, additional proteins are recruited to the miRISC to mediate 
silencing [31]. miRNAs can mediate the silencing of mRNA by inhibiting translation, or 
promoting mRNA instability through the deadenylation and decapping of the 5ʹ- and 3ʹ-ends 
therefore accelerating degradation [31].  It’s believed that miRNA-mediated degradation of 
mRNA accounts for approximately 66-90% of miRNA function in cultured cells [32]. The 
cytoplasmic nuclease 5ʹ-to-3ʹ exoribonuclease 1 (XNR1) is responsible for degrading the 
deadenylated and decapped mRNAs. miRNA-mediated translational repression accounts for 6-




Figure 2.  MicroRNA Biogenesis. Figure adapted from [19]. 
 
MiRNAs and cancer 
The function of miRNAs are critical for the proper function of embryonic development [34].  
During differentiation, the global expression of miRNAs increase in order to define tissue-
specific gene expression patterns  [35].  The global downregulation of miRNAs has been 
observed in a variety of tumor types [35].  Alterations in miRNA processing and function have 
been identified in nearly every cancer type [19] and are involved with a variety of cancer 
promoting processes, including proliferation [36], migration [37], invasion [38], apoptosis [39], 
and angiogenesis [40].  Disruption of normal miRNA expression by inhibiting any of the critical 
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miRNA processing proteins was shown to promote tumorigenesis [41].  Furthermore, the 
aberrant expression of DICER1, AGO2, and XPO5 was identified in multiple cancer types, 
including breast, ovarian and melanoma [42, 43].  The expression profile of miRNA signatures 
has been correlated with cancer prognosis, diagnosis, progression, and clinical outcome.  
 
The altered transcriptional expression of specific miRNAs can be mediated by aberrant DNA 
methylation.  Approximately 20% of miRNAs are located within regions of DNA known as sites 
of methylation, called CpG islands [44].  One particular microRNA of interest is miR-137 which 
is located within a non-protein-coding gene AK094607, on chromosome 1p22 [45].  miR-137 is 
embedded in a CpG island, and is silenced in multiple cancer types following hyper-methylation 
of its promoter region, including colorectal [46], gastric [47], uveal melanoma [48], oral cancer 
[49], glioblastoma multiforme [50], squamous cell carcinoma of head & neck [51, 52], and breast 
cancer [53].   
 
In this study, we show evidence that RNA binding proteins Musashi-1 (MSI1) and Musashi-2 
(MSI2) are both negatively regulated by miR-137.  Additionally, miR-137 acts as a tumor-
suppressive miRNA, in part by negatively regulating Musashi-1 and possibly Musashi-2.  
 
Discovery of Musashi-1  
The Musashi family of RNA-binding proteins is made up of MSI1 and MSI2. First identified in 
Drosophila, MSI1 plays a critical role in the asymmetrical division of sensory organ stem cells 
[54].  During asymmetrical division of the sensory organ precursor cells, the daughter cells split 
into a non-neural precursor cell and a neural precursor cell. In MSI1 mutants, two non-neural 
precursor cells are produced giving rise to hair-forming cells and a double-bristle phenotype, as 
8 
 
opposed to the single-hair wild-type phenotype [54].  Musashi was named after a Japanese 
samurai warrior, Miyamoto Musashi, who fought with two swords [55].  Later studies found that 
MSI1 promotes the neural differentiation of one daughter cell by repressing the translation of 
Tramtrack69 (TTK69) protein [56].   
 
Musashi proteins repress the translation by binding to the 3ʹUTR of target RNA while also 
binding to the poly(A)-binding protein (PABP) and inhibiting it’s interaction with the 
translational activation protein eIF4G [57, 58].  Collectively, studies indicate the major function 
of MSI1 is to repress the translation of target mRNA.  However a few studies have highlighted a 
translational activation mechanism for MSI1, although the mechanism controlling the 
translational activation function of MSI1 is not well understood.   
 
To identify RNA binding motifs of MSI1, researchers used an in vitro selection method known 
as systematic evolution of ligands by exponential enrichment (SELEX) [56]. They discovered 
that mouse MSI1 preferentially binds to sequences containing two or three repeats of 
GUU…UAG or GUU…UG. In a separate study, RNA targets of mouse MSI1 was identified 
using SELEX method.  Similarly, this study found that mouse MSI1 preferentially binds to the 
RNA sequence (G/A)UnAGU [n = 1-3] [59].   
 
In humans, the mRNA targets for MSI1 were identified using an RNA immunoprecipitation 
(RIP)-Chip assay [60].  A total of 64 mRNA targets were identified. The genes belong to two 
main functional categories; 1) cell cycle, proliferation, differentiation and apoptosis, and 2) 
protein modification.  Both functional categories are pertinent to tumorigenesis. From this study, 
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proteomic analysis revealed that MSI1 can negatively regulate or promote the translation of 
mRNA targets [60].  
 
Musashi-1 positively regulates Notch and Wnt signaling  
Notch and Wnt signaling are two important signaling cascades involved in the initiation and 
progression of cancer, reviewed in [61, 62].  Notch signaling influences many cell fate decisions, 
such as; differentiation, apoptosis and proliferation [63]. Notch signaling is mediated through the 
cleavage of the NOTCH intracellular domain (NICD) and the translocation of NICD to the 
nucleus where it acts as a transcriptional co-activator to initiate the expression of Notch target 
genes, such as hairy and enhancer of split-1 (HES1) [64].  Notch signaling is negatively 
regulated by numb homolog (NUMB) binding to and preventing the cleavage of NICD [65].  
MSI1 positively regulates Notch signaling by negatively regulating NUMB translation by 
interacting with the cis-acting repressor motif, GU3-5(G/AG), in the 3ʹUTR [59].  
 
Wnt signaling is another important signaling pathway involved in cancer initiation and 
progression [62, 66].  During canonical Wnt signaling, β-catenin accumulates in the cytoplasm 
and translocates to the nucleus. β-catenin acts as a transcriptional co-activator by binding to T 
cell-specific transcription factor/lymphoid enhancer-binding factor 1 (TCF/LEF1) transcription 
factors to initiate expression of Wnt target genes; such as v-myc myelocytomatosis viral 
oncogene homolog (MYC) and cyclin D1 (CCND1), reviewed in [67]. The destruction complex 
comprised of Axin, adenomatous polyposis coli (APC) and glycogen synthase kinase 3β (GSK-
3β) negatively regulate Wnt signaling by binding to β-catenin and marking it for degradation 
through ubiquitination (reviewed in [68]).  MSI1 promotes Wnt signaling by binding to the 
10 
 
3′UTR and negatively regulating the translation of APC [69].  APC is a well-characterized tumor 
suppressive protein and an inhibitor of Wnt signaling [70].    
 
In intestinal epithelial primary cultures derived from the small intestine of neonatal mice, MSI1 
knock-in increases Wnt signaling by upregulating the expression of frequently rearranged in 
advanced T-Cell lymphomas 1 (FRAT1), although the exact mechanism is unknown [71].  
FRAT1 enhances Wnt signaling by promoting the accumulation of β-catenin [72, 73].  
Additionally, MSI1 expression in mammary progenitor cells decreases the expression of the 
secreted Wnt inhibitor, Dickkopf-3 (DKK3) [74]. However, the mechanism responsible for 
MSI1-mediated down regulation of DKK3 is unclear.  Collectively, MSI1 promotes Wnt 
signaling by negatively regulating APC and DKK3 and upregulating FRAT1.   
 
Additional functions of Musashi-1  
MSI1 promotes the growth of cells by regulating multiple mechanisms.  MSI1 promotes cell 
cycle progression by negatively regulating the translation of p21cip1 [75].  Additionally, studies 
have shown that MSI1 upregulates proliferation by increasing the growth factor, proliferin 
(PLF1) [74].  However the specific mechanism associated between MSI1 and PLF1 expression 
has not been studied.  
 
In mouse embryonic brain tissue, MSI1 negatively regulates the protein translation of 
doublecortin (DCX) by binding to the 3′UTR [76]. DCX is expressed primarily in neuronal 
precursor cells newly differentiated from neural stem cells.  DCX promotes the migration of 
newborn neurons [77].  Therefore, MSI1 negatively regulates the migration of neural stem cells 
by inhibiting the translation of DCX.  
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Localization of Musashi-1 
To date, there remains much ambiguity in regards to the precise subcellular localization of MSI1 
[78].  Depending on the cell type, MSI1 has been reported to be localized predominantly in the 
cytoplasm, diffused evenly throughout the cell, or localized in the nucleus. In neuronal stem and 
progenitor cells, MSI1 is predominately located in the cytoplasm, although, MSI1 can be 
localized in the nucleus [79, 80].  Using a GFP-tagged, full-length protein, MSI1 was found 
evenly distributed in the cytoplasmic and nuclear compartments in neural progenitor cell line, 
PC12. Upon differentiation, MSI1 was predominately expressed in the nucleus. These results 
suggest that MSI1 is sequestered in the nucleus during differentiation in order to de-repress 
MSI1 target mRNAs. (unpublished data, mentioned in the review article [81]).  The conflicting 
results highlight an important need to study the localization of MSI1 further.  A nuclear 
localization signal (NLS) sequence is found within the highly conserved MSI1 RNA binding 
domain 1 (RBD1).  Since RBD1 is the major domain for binding to RNA, interaction with target 
mRNA in the cytoplasm may inhibit the NLS signal and MSI1 localization to the nucleus [82].  
 
The nuclear function of MSI1 is largely unknown. Recently, a study found that MSI1 is 
responsible for the RNA maturation of TAU in the nucleus of neurons, suggesting that MSI1 may 
have distinct nuclear functions [83].  In neuronal stem/progenitor cells, MSI1 can be localized in 
the nucleus where it post-transcriptionally regulates miRNAs along with Lin28 [79].  Lin28 is a 
microRNA binding protein that will bind to pre-miRNAs and prevents maturation [84]. 
Collectively, the data suggests that the regulatory mechanism responsible for the localization of 





Expression of Musashi-1 in normal tissues 
Adult stem cells have been identified in multiple tissue types and are essential in maintaining 
proper organ function and response to damage.  So far, adult stem cells have been identified in 
the hematopoietic system, mammary gland, testis, skeletal muscle, skin, intestine, hair follicles, 
myocardium and the central nervous system (CNS). MSI1 is most famously known for its role in 
maintaining stem cell function.  The expression of MSI1 has been identified in a variety of adult 
stem cell populations, including the mouse eye [85], intestine [86], stomach [87], mammary 
gland [88], hair follicle [89], and the CNS [55].   
 
In order to gain a better understanding of the expression of Musashi1 in the developing intestinal 
tissues, Asai et al., tracked the expression of MSI1 in the developing intestinal organs in chicken 
and mice [90].  During the early stages of development, MSI1 is broadly expressed in both the 
developing stomach and intestine and located in endoderm and mesenchymal derivatives. In later 
morphogenetic stages, MSI1 expression is restricted to the epithelia. After crypt formation in the 
intestinal tract, MSI1 is restricted to a few cells at the base of the mature crypt [86, 90, 91].   
 
In the intestinal epithelium, stem cells are located at the base of the crypts of Lieberkühn, and 
responsible for the constant cell renewal, with a single crypt producing approximately 250 new 
epithelial cells each day [92]. The lining of the intestinal track is renewed every week. As cells 
migrate up the transit amplifying region of the crypt, the stem progenitor cells begin to 
differentiate into mature intestinal cells.  Once they reach the top, cells are finally shed into the 
lumen and undergo apoptosis [93].  Two populations of stem cells have been identified in the 
small intestine; actively cycling stem cells expressing the marker leucine-rich repeat containing 
G protein-coupled receptor 5 (LGR5) and the quiescent stem cells located at the +4 position at 
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the base of the crypt, expressing BMI1 proto-oncogene, polycomb ring finger (BMI1) [92, 94]. 
MSI1 is expressed in both stem cell populations [92].  
 
Musashi: stem cell marker of the intestinal epithelium 
Multiple studies have provided evidence that MSI1 is a marker of stem cells in the intestinal 
epithelium.  MSI1+ cells have the ability to retain DNA labeling after several rounds of cell 
division, a characteristic of stemness [86, 90, 91].  MSI1 cells also express the LGR5 
proliferating stem cell marker [95].  Shown in mice, MSI1+ cells express the Notch signaling 
target gene and stemness regulator, HES1 [86, 90].  After injury to the small-intestine in mice, 
MSI1+/HES1+ cells enhanced tissue regeneration, a characteristic of stem cells [96]. Using an 
elegant reporter mouse model with a GFP knock-in within the LGR5 locus [97], researchers 
studied the stem cell signature using cell sorting and transcriptomic and proteomic analysis.  
MSI1 was identified as a stem cell signature gene in the intestinal LGR5+ stem cell populations.  
 
Although there is compelling evidence that MSI1 is associated with stem cell status in intestinal 
tissues, few studies have shown the function of MSI1 in normal intestinal physiology. In an in 
vitro model, MSI1 was shown to be responsible for the proliferative capability of intestinal 
epithelial progenitor cells by up regulating both Wnt and Notch signaling pathways [71]. 
Additionally, MSI1 negatively regulates NUMB, an important inhibitor of Notch signaling. In 
asymmetric cell division, NUMB and NOTCH1 are heterogeneously expressed in daughter cells, 
therefore NUMB defines the differentiating daughter cell, while the NOTCH1 daughter cell 
retains stem cell status [59].  This data suggests that MSI1 is directly involved in inhibiting the 
differentiation of intestinal stem/progenitor cells by negatively regulating NUMB.    
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Recently, a study found that MSI2 plays a role in the transformation of the intestinal epithelium 
[98].  Using an intestinal specific MSI2 knock-in mouse model, they found that MSI2 promotes 
the expansion of LGR5+ stem cells, increases crypt proliferation and fission. This is the first 
study to report MSI2 function in the intestinal epithelium. 
 
Musashi1 expression in adult stem cells 
In the CNS, MSI1 is predominately expressed in undifferentiated neural stem and progenitor 
cells within the peri-ventricular area of mouse embryos and postnatal mammalian brains [55, 99, 
100].  The expression of MSI1 is rapidly shut-down in post-mitotic neurons, although the 
mechanism is not understood [55].  The proliferation and self-renewal of neural stem and 
progenitor stem cells is maintained by MSI1-mediated down regulation of NUMB and 
subsequent activation of Notch signaling [59, 78].  Unlike MSI1, MSI2 is expressed in neural 
precursor cells and is continuously expressed in mature neurons in the neocortex and basal 
ganglia [100].  
 
In the stomach, MSI1 was detected in the isthmus/neck region, the putative location of stem cells 
[87].  In the mammary gland, putative stem cells were identified using MSI1 antibodies [88].  
MSI1 is highly expressed in CD24hi/CD133+ cells, markers for breast progenitor cells [101].  The 
proliferation and expansion of mammary progenitor cells is driven by a MSI1-dependent 
autocrine process [74].  MSI1 increases the secretion of PLF1 and reduces the secretion of Wnt 
inhibitor, DKK3. This results in the enhancement of Wnt and Notch signaling and increased 
CD24hi/Sca-1+ and CD24hi/CD29+ cells, markers for breast progenitor cells (Figure 3). It’s 
important to note that MSI1 did not drive the expansion of the breast stem cells, but rather 
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progenitor cells with multipotent differentiation capabilities [74].  CD24hi/CD29+ mammary cells 









Figure 3. MSI1 maintains the proliferation of breast progenitor stem cells with multipotent 
differentiation potential [74].  
 
Regulation of Musashi proteins 
Multiple studies have shown that MSI1 is positively regulated by the canonical Wnt pathway.  
MSI1 is expressed in the intestinal tumors of APCmin/+ mice, suggesting that MSI1 is 
downstream of Wnt signaling [86].  One study identified a functional Tcf/Lef binding sites 6 kb 
upstream of mouse MSI1 transcriptional start site [71].  Additionally, MSI1 is transcriptionally 
upregulated by Wnt signaling stimulation.  Using human colonocytes, Wnt-mediated activation 
of MSI1 was found to be inhibited upon knock-down of APC [69].  Inversely, this study found 
that MSI1 can negatively regulate APC by binding to its 3′UTR and preventing protein 
translation.  Collectively, these studies provide significant evidence that MSI1 is a Wnt target 
gene and also a promoter of Wnt signaling.  
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The mRNA of MSI1 is stabilized by RNA binding proteins, human embryonic lethal abnormal 
vision (Hu/ELAV) family orthologs; HuB, HuC, HuD, and HuR, by binding to the AU-rich 
elements in the MSI1 3′UTR [103, 104]. The oncogenic nature of HuR, also known as ELAV1, 
was shown to be mediated by an upregulation of MSI1 in glioblastoma cells [103].  HuR knock-
down HuR reduces the stability of MSI1 mRNA and protein translation [103].     
 
The expression of insulin-like growth factor 2 (IGF2) increases the number of MSI+ mammary 
stem and progenitor cells and promotes tumorigenesis. However, the specific mechanism 
mediating IGF2-dependent MSI1 expression is currently unknown and needs to be studied 
further [74].  During neuronal differentiation, MSI1 expression is down regulated, although the 
specific mechanism mediating the down regulation of MSI1 has not been studied [75, 105].  It’s 
possible that microRNAs are mediating the down-regulation of MSI1 during differentiation of 
neural, breast and intestinal stem cells.   
 
Stimulation of Notch3 receptor (not Notch1/2) by the notch ligand Delta-like (DLL)-4, increased 
the expression of MSI1 mRNA and protein in colorectal cancer cell lines, MICOL-14tum and 
LoVo along with primary cultures of CRC metastases samples [106].  This study revealed a 
novel Notch signaling feed-forward loop where Notch 3 activates MSI1, which indirectly 
activates Notch 1 signaling by down regulating NUMB.  However, the mechanism of Notch3-
dependent activation of MSI1 is unknown.  It is likely that Notch 3 signaling increases the 
expression of MSI1 in an indirect mechanism. When cells were transfected with a plasmid 
containing the MSI1 promoter sequence downstream of a luciferase gene, activation of Notch 3 
did not stimulate the expression of luciferase. Additionally, in ovarian cancer cells, the MSI1 
promoter sequence was not found to be bound to the Notch3 complex in a ChIP-on-ChIP study 
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[107].  These results suggest that Notch 3 stimulates the expression of MSI1 indirectly, possibly 
through a microRNA-mediated mechanism.  
 
As for the regulation of MSI2, one study found that MSI2 contains a homeobox 9 (HOXA9)-
binding element at -5.7 kb upstream of its transcriptional start site [108].  HOXA9 can bind to 
MSI2 promoter region and initiate the transcriptional activation of MSI2.  This level of 
regulation is highly relevant for myeloid leukemia. A well characterized oncogenic fusion 
protein NUP98-HOXA9 is responsible for the progression to blast crisis phase, the advanced and 
aggressive form of chronic myeloid leukemia [109].  NUP98-HOXA9 activates the transcription 
of MSI2, leading to an increased expression level of MSI2 in blast crisis phase and a less 
differentiated phenotype [108].  
 
Since Musashi proteins are so commonly overexpressed and associated with tumorigenesis, 
metastasis and poor overall survival for patients with a variety of cancer types (reviewed in detail 
in Chapter 2), the specific regulation of MSI needs to be extensively studied. One advantage of 
understanding the mechanisms associated with MSI1 overexpression in cancer is the 
development of potential anti-cancer therapeutics targeting MSI.  Additionally, by understanding 
the mechanisms of MSI regulation, we hope to gain a better understanding of cancer etiology and 
possibly cancer prevention.  For example, one study found that MSI1 expression was increased 
in response to helicobacter pylori infection in the human gut [110].  Maybe the increased 
expression of MSI1 in cancer is initially caused by an overactive wound-healing response that 
can be more easily controlled during the early stages of disease. Since APC is so commonly 
mutated in colon cancer and is known to inhibit Wnt signaling and MSI1 expression [69], maybe 
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the loss of functional APC is the initiating event that leads to an overexpression of MSI1 in 
cancer.   
 
MSI1 mRNA contains a long 3ʹUTR (~1800 nucleotides) consistent with possible post-
transcriptional regulation by miRNAs.  The average 3ʹUTR  length of miRNA target genes is 
approximately 1600 nucleotides, as compared to non-miRNA target genes, 1000 nucleotides 
[111]. Recently, miRNAs negatively regulating MSI1 mRNA were identified and found to be 
dysregulated in glioblastoma [112].  Co-transfection of putative targeting miRNAs with the 
MSI1 3′UTR luciferase reporter resulted in decreased luciferase activity indicating miRNA-
mediated translational repression. This study, investigating the role of miRNA regulation of 
MSI1 in glioblastoma, provides substantial precedent that miRNAs regulate MSI1.                                              
 
In the coming chapters, we provide evidence that Musashi proteins are negatively regulated by 
microRNAs. Specifically miR-137 acts as a tumor suppressive microRNA, in part by negatively 
regulating MSI1 and possibly MSI2.  We provide a comprehensive review of the expression of 
Musashi proteins in a variety of cancer types along with the correlation with clinical outcome. 
Finally, we report preliminary data on the development of novel small molecule inhibitors of 
MSI1. Using NMR, the binding interaction between MSI1-RBD1 and hit compounds was 
characterized.  Overall, our studies illuminate a novel mode of anti-cancer therapy targeting 
Musashi RNA binding proteins using either microRNA-based molecular therapy or small 
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In the new age of precision medicine, initiatives are being heavily pursued on defining the 
molecular subtypes of cancer and determining the best therapeutic strategy for a given genomic 
and molecular tumor landscape [1].  The future of molecular oncology will focus on 
understanding the molecular attributes of an individual tumor to inform treatment decisions, 
much like building a map of a person’s cancer to better formulate an attack.  Precision oncology 
will require a coupling of molecular profiling with pathological indexes to improve diagnostic, 
prognostic and therapeutic strategies.  
 
Musashi proteins have been reported to be involved with tumorigenesis in multiple adult tissues: 
including glioblastoma, colon, breast, lung, ovarian and leukemia.  This chapter will provide a 
comprehensive review of the expression of Musashi in patient tumor samples (summarized in 
Table 1), the correlation with patient outcome, and evidence for Musashi induced malignancy.  




Using a tissue microarray (TMA) from a cohort of patients with colorectal cancer, researchers 
used immunohistochemistry (IHC) to measure the expression of MSI1 [2].  They found that 
MSI1 protein expression gradually increased from normal colon mucosal tissue to advanced 
stage colorectal adenocarcinoma. MSI1 was detected in 50% (n = 8) of colorectal adenoma 
samples and was highly expressed in 66.7% (n = 69) of colorectal carcinoma tissues [2].  High 




In a separate study, researchers measured the expression of MSI1 in a TMA consisting of 203 
primary colon cancer and matching normal colon mucosa and 66 lymph node metastasis (LNM) 
and correlated the expression level of MSI1 with clinical outcome [3].  Interestingly, they found 
that MSI1 was strongly expressed in the nucleus of colon cancer cells.  MSI1 was highly 
expressed in 64.5% (n = 203) of primary colon cancer tumors and 87.9% (n = 66) of LNM.  High 
expression of MSI1 positively correlated with invasion depth, distant metastasis, clinical stage 
and Ki67 staining (a marker for proliferation).  Patients with MSI1+ tumors developed metastasis 
more than patients with MSI1− tumors (P<0.001).  Additionally, patients with MSI1+ tumors had 
an increased risk of developing distant metastasis (HR = 5.1, P < 0.001) and poor 5-year overall 
survival (HR = 3.8) as compared to patients with MSI1− tumors. In RKO cells, an invasive colon 
cancer cell line, knock-down of MSI1 significantly decreased cell growth, migration and 
invasion [3].  
 
The mRNA level of MSI1 was shown to be increased (greater than 2-fold) in 66.7% (n = 15, 
P<0.01) of primary colorectal tumors as compared to adjacent normal mucosal tissue [4].  
Additionally, MSI1 knock-down using siRNA, inhibits the xenograft tumor growth of HCT-116 
colon adenocarcinoma cells as compared to cells treated with a negative control siRNA.  
 
We recently studied the expression of MSI1 in tissue samples from patients with rectal cancer 
(discussed at length in Chapter 3) [5]. MSI1 was strongly expressed in 79% of primary rectal 
tumors (n = 146), 53% of LNM (n = 49), 1% of distant normal rectal mucosa (n = 118), and 8% 
of adjacent normal rectal mucosa (n = 80). The correlation between expression of MSI1 and 
clinical outcome was determined using publically available microarray data coupled with clinical 
parameters using PrognoScan [6]. We found that high expression of MSI1 significantly 
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correlates with poor overall survival in patients with multiple cancer types, including colorectal, 
bladder, acute myeloid leukemia (AML), and ovarian cancers [5].  
 
The expression of MSI2 was recently measured in tissue samples from patients with colorectal 
cancer [7].  Using The Cancer Genome Atlas (TCGA), MSI2 mRNA was analyzed in 314 
healthy colon mucosal tissue samples and 314 colon adenocarcinoma tissue samples (non-
matching).  The expression of MSI2 mRNA was consistently increased in tumor samples as 
compared to normal mucosal tissue.  Additionally, the expression of MSI2 protein was measured 
in tissue samples using IHC.  The expression of MSI2 gradually increased with increasing grade 
of colorectal adenocarcinoma, suggesting that MSI2 may be involved with the progression of 
colon cancer [7].   
 
Gastric cancer 
Biopsy and surgical tissue samples from patients with gastric cancer were obtained and stained 
for MSI1 [8].  MSI1 protein expression is significantly higher in intestinal-type gastric cancer 
than normal gastric mucosa (P < 0.05). The expression of MSI1 was weak in normal gastric 
mucosa samples. There was no statistical significance in the expression of MSI1 between low 
and high-grade intraepithelial neoplasia (P < 0.05), suggesting that MSI1 expressing cells may 
play an early role in the development of gastric cancer.  MSI1 expression in gastric cancer 
positively correlated with lymph node metastasis (P < 0.01), suggesting that MSI1 cells may be 







In hepatocellular carcinoma (HCC), MSI1 and MSI2 were found to be upregulated in 38% and 
49% respectively, in tumor tissue samples as compared to 5% and 8% of adjacent normal hepatic 
tissues (n = 149) [9].  Interestingly, MSI1 was expressed primarily in the cytoplasm whereas 
MSI2 was expressed primary in the nucleus of HCC samples.  Although MSI1 and MSI2 were 
both overexpressed in HCC, only MSI2 was correlated with large tumor size, multiple tumor 
lesions, invasion, stage and early recurrence.  Specifically, high expression of MSI2 was 
correlated with poor overall survival (P < 0.0001) and tumor recurrence (P < 0.0001).   High 
expression of MSI1 was correlated with solitary lesions.  
 
Breast cancer  
In normal breast tissue, MSI1 is expressed in ~1% of ductal epithelial cells in the terminal ductal 
lobular unit of normal human breast tissue, the site where breast cancer is thought to be initiated 
[10].  MSI1 was expressed in 55% (n = 20) of human breast cancer cell lines and shows a strong 
positive correlation with the expression of ErbB2.  MSI1 expression was enriched in isolated 
breast cancer stem cell marker CD133+ cells as compared to CD133− cells. In patient samples, 
MSI1 was over-expressed in 51% (n = 140) of primary breast tumor samples and 84% (n = 19) 
of metastatic lesions in the lymph nodes.  Patients with high expression of MSI1 in their tumors 
survived less than patients with low expression of MSI1 (P = 0.0402), suggesting that MSI1 is a 
negative prognostic marker for patients with breast cancer.  Additionally, MSI1 knock-down 
reduced tumor growth of breast cancer cells MCF-7 and T47D xenografts by approximately 50-







Using a TMA, the expression of MSI1 was analyzed using IHC in 103 tumor samples from 
patients with medulloblastoma along with 10 normal cerebellum tissue samples used for control 
[11]. MSI1 expression was significantly higher in the medulloblastoma samples as compared to 
the expression of MSI1 in the normal cerebellum tissues [11].  
 
In a separate study using 259 tumor samples from patients with medulloblastoma compiled in a 
tissue microarray, the expression of MSI1 was studied [12]. MSI1 staining was negative in 23% 
(n = 59/259) of samples and strongly expressed in 77% (n = 200/259) of tumor samples. High 
MSI1 was significantly correlated with poor overall survival and progression-free survival. The 
samples were separated into molecular subtypes of medulloblastoma; SHH, WNT, groups 3 & 4.  
High MSI1 expression was frequently observed in groups 3 & 4.  Specifically, 98% of samples 
with group 3 molecular subtype had high expression of MSI1.  Additionally, in groups 3 & 4, 
high expression of MSI1 is associated with poor prognosis and overall survival as compared to 
MSI1− tumors. Daoy (medulloblastoma cell line) xenografts treated with MSI1-siRNA grew 
significantly less than tumors treated with a negative control siRNA. A RIP-ChIP experiment 
was done to identify mRNAs associated with MSI1 protein in Daoy cells. The mRNAs bound to 
MSI1 protein were then subjected to a microarray and analyzed using pathway analysis software. 
They found that MSI1-associated mRNAs are involved with many cancer relevant processes; 
such as apoptosis (44%), cell cycle (24%), cell differentiation (40%), cell proliferation (46%), 







In human hematopoietic stem cells, MSI2 is expressed at much higher levels than MSI1 [13]. 
MSI2 is highly expressed in the blast crisis phase (n = 30), the aggressive form of chronic 
myeloid leukemia (CML) in which the treatment outcome is extremely poor. Researchers then 
used a separate microarray study and found that MSI2 was overexpressed in 100% of patients in 
blast crisis phase (n = 90) [13].  In patients with chronic phase of CML, high expression of MSI2 
is positively correlated with a high risk of relapse (HR = 4.35, P = 0.07, n = 37).  In patients with 
blast crisis phase, high expression of MSI2 is positively correlated with high risk of relapse (P = 
0.06) and a high risk of death (HR = 6.76, P = 0.08) [13].        
 
In acute myeloid leukemia, MSI2 protein is expressed in the nucleus and cytoplasm of 70% of 
patients tumor samples (n = 120) [14].  High expression of MSI2 was observed in 33% of 
patients and was correlated with poor outcome (P < 0.0001).  Interestingly, nuclear MSI2 was an 
independent predictor of poor outcome.  This is the first study to show that nuclear MSI2 may be 
an independent marker for prognosis.  
 
Endometrial carcinoma 
The endometrium is the inner lining of the uterus. Growth of endometrial tissue outside of the 
uterine cavity is referred to as endometriosis [15].  Moderate staining of MSI1 protein was 
observed in 50% (n = 16) endometriosis cases and 75% (n = 9) of endometrial carcinomas as 
compared to normal endometrial tissue samples [16].  The cytoplasmic expression level of MSI1 
progressively increased in early adenomyosis to endometroid carcinoma samples, suggesting that 





Lung carcinoma       
MSI1 is enriched in CD133+ (cancer stem cell marker) cells, in A549 and NCI-H520, 
bronchioalveolar carcinoma and squamous cell carcinoma cell lines [17].  Knock-down of MSI1 
significantly reduced spheroid colony formation. MSI1 protein is highly expressed in 86% (n= 
202) of primary lung carcinomas and rarely detected in adjacent normal lung tissue. In primary 
lung carcinoma tissue samples, MSI1 is expressed cytoplasmic in a diffuse pattern 50% of the 
time. In bronchioscopic biopsy samples, MSI1 mRNA is increased in 80% (n = 188) of 
malignant samples and rarely detected in non-malignant diseased tissues [17].  Since MSI1 was 




The expression of MSI1 was studied using IHC and a TMA made up of tissue samples collected 
from normal cervix tissue, cervical carcinoma in situ and invasive cervical carcinoma tissues 
[18]. MSI1 staining was found to be equally localized throughout the nucleus and cytoplasm of 
normal and cancer tissues.  MSI1 positive staining was found in 30% (9/30) of normal cervical 
tissue, 43.3% (13/30) of cervical carcinoma in situ tissue and 81.4% (48/59) of invasive cervical 
carcinoma tissue. MSI1 expression was significantly increased in cervical carcinoma [18]. 
Furthermore, they show that knocking down MSI1 in HeLa cells (cervical cell line), significantly 
reduced the proliferation in vitro and inhibited xenograft tumor growth, suggesting that MSI1 
may be a therapeutic target for cervical cancer.  
 
In a separate study, the expression of MSI1 was analyzed using IHC on a TMA comprised of 
tissue samples from 235 patients with various degrees of cervical cancer [19].  MSI1 expression  
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was found to be significantly increased in the mild dysplasia and moderate-severe dysplasia as 
compared to normal cervical epithelia.  Additionally, MSI1 expression was even stronger in 
squamous cervical carcinoma tissue samples. Collectively, the data suggest that MSI1 may be 
involved in the progression of cervical cancer.   
 
Glioma cancers 
One study measured the percentage of MSI1+ cells in 73 glioma samples and 3 normal brain 
tissue samples [20].  The study included samples from glioblastoma multiforme, anaplastic 
astrocytomas, astrocytomas, oligodendrogliomas, anaplatic oligoastrocytomas and 
oligoastrocytomas.  In normal adult and fetal brain tissue, MSI1 was localized in the ventricular 
and subventricular zones and within glial and astrocyte cells.  The neural stem cell population is 
thought to reside in the periventricular zone of both adult and fetal brains [21].  MSI1 protein 
was highly expressed in 73.9% (17/25) of glioblastoma multiforme, 29.4% (5/17) anaplastic 
astrocytomas, and 18.8% (3/16) astrocytomas tissue samples. MSI1 was not expressed in pure 
oligodendroglioma tissue samples but was found in oligoastrocytomas and anaplastic 
oligoastrocytomas.  The percentage of MSI1 cells increased in association with increased 
astrocytoma grade and also correlated with proliferation.  This data suggests that MSI1 plays a 








Table 1:  Expression of Musashi-1 and Musashi-2 in Cancer 
HR = Hazard Risk, OS = Overall survival, TMA = tissue microarray, IHC = Immunohistochemistry 








value Noteworthy Observations Reference 
Rectal Primary 
Tumors a 
79 21 146 Determined using TMA and IHC.  [5] 
Rectal lymph node 
metastasis a 
53 47 49 Determined using TMA and IHC. [5] 
Colon primary 
tumors b 
64.5  203 Determined using IHC.  Strong Msi1 correlated with 
stage, metastasis, distant metastasis and + Ki-67 staining, 
poor overall survival 
[3] 
Colon lymph node 
metastasis b 
87.9  66 Determined using IHC. [3] 
Colorectal 
adenomas a, b 
50 50 8 Determined using TMA and IHC. High MSI1 correlated 
with TNM stage 
[2] 
Colorectal 
adenocarcinoma a, b 
66.7 33.3 69 Determined using TMA and IHC [2] 
Colorectal 
adenocarcinoma 
66.7 33.3 15 MSI1 mRNA. Determined using qRT-PCR [4] 
Primary Breast 
Cancer 
51 49 140 Determined using IHC. High Msi1 correlated with poor 
survival.  
[10] 
Breast lymph node 
metastasis 
84 16 19 Determined using IHC.  [10] 
Hepatocellular 
carcinoma b 
37.6 62.4 149 Correlated with solitary lesions. Not correlated with OS.  [9] 
Endometrial 
carcinoma a 
75  9 Determined using IHC [16] 
Medulloblastoma 77 23 259 Determined using TMA and IHC. 
Significantly correlated with molecular subtypes: groups 




81.4 18.6 59 Determined using TMA and IHC.  [18] 
Lung primary 
cancer a 
86 14 202 Determined using TMA and IHC.  [17] 
Glioblastoma 
multiforme 
73.9 26.1 25 IHC [20] 
Anaplastic 
astrocytomas 
29.4 70.6 17 IHC [20] 








value Noteworthy Observations Reference 
Hepatocellular 
carcinoma b 
49 51 149 High Msi2 correlated with large tumor burden, invasion,  






100  90 Associated with high risk of relapse and death [13] 
Acute myeloid 
leukemia b 
33 77 210 High MSI2 was correlated with poor outcome (P < 




Musashi proteins: potential diagnostic and prognostic biomarkers 
In support of the new precision medicine initiative, there is a clear need in identifying diagnostic 
and prognostic biomarkers.  The success of curing cancer patients is greatly increased by early 
detection along with administering therapy best suited to attack a patient’s tumor type.  Multiple 
studies have shown that MSI proteins may serve as diagnostic and prognostic biomarkers for a 
wide range of cancer types.   
 
Breast cancer is a highly heterogeneous disease and has been organized into multiple molecular 
subtypes [23].  Patients with high expressing MSI1 primary breast tumors are at greater risk for 
death as compared to patients with low MSI1 expressing tumors [10].  One weakness of this 
study is that the expression of MSI1 was not correlated with the molecular subtype of breast 
cancer.  The breast cancer patient cohort included a range of molecular subtypes.  Although this 
study provides significant precedents that MSI1 may be a negative prognostic biomarker for 
breast cancer, future studies need to examine the expression and function of MSI1 in different 
subtypes of breast cancer.     
 
In colon cancer tumors, MSI1 was highly expressed in the nucleus [3]. Furthermore, they found 
that high expression of MSI1 was correlated with poor 5-year survival.  This study suggests that 
nuclear MSI1 may be a negative prognostic biomarker for colon cancer.  In rectal cancer, MSI1 
was found to be highly expressed in the cytoplasm of rectal cancer cells and very weak staining 
in adjacent and distant normal rectal mucosal tissue [5]. Additionally, high expression of MSI1 
mRNA in colorectal tumor tissues was correlated with poor overall survival in patients [5]. Since 
MSI1 is not highly expressed in normal tissues, high expression of MSI1 may also be used as a 
diagnostic marker for colorectal cancer. In gastric cancer tumor samples, MSI1 was highly 
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expressed in early epithelial neoplasias and barely detected in normal gastric mucosa samples, 
suggesting that MSI1 may be used as an early detection marker for gastric cancer [8].     
 
High expression of MSI1 was significantly associated with poor overall survival and 
progression-free survival for patients with medulloblastoma [12].  More specifically, high 
expression of MSI1 in molecular subtypes 3 & 4, is associated with poor prognosis and overall 
survival as compared to MSI1– tumors. This data suggests that MSI1 may be a promising 
diagnostic marker for subtypes 3 & 4 medulloblastoma and a negative prognostic marker.   
 
In hepatocellular carcinoma, MSI1 and MSI2 were highly expressed in 38% and 49% of tumor 
tissue samples respectively [9].   However, only high expression of MSI2 was correlated with 
poor overall survival and tumor recurrence.  Interestingly, MSI2 was high expressed in the 
nucleus of hepatocellular carcinoma cells, suggesting that nuclear MSI2 may be a promising 
prognostic biomarker.  
 
In CML, high expression of MSI2 is correlated with high risk of relapse and high risk of death 
[13]. In AML patients, high MSI2 was correlated with poor outcome and more specifically, high 
expression of nuclear MSI2 was a predictor of poor outcome [14]. Altogether, high expression of 
MSI2 may serve as a negative prognostic biomarker for patients with CML and AML.   
 
Interestingly, strong expression of nuclear MSI1 and MSI2 has been observed in multiple cancer 
types, including colon, cervical, hepatocellular carcinoma and acute myeloid leukemia and 
associated with poor clinical outcome. The nuclear function of Musashi proteins is vastly 
understudied.   In future studies, measuring the expression of Musashi proteins in specific 
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locations within the cell, along with correlating the expression with molecular subtypes will 
greatly enhance our current knowledge of using MSI as prognostic and diagnostic biomarkers. 
Collectively, the over expression of Musashi proteins is associated with poor clinical outcome in 
multiple cancer types and are promising prognostic markers.  
 
Evidence for Musashi induced malignancy 
Musashi proteins may act as oncogenic triggers by inhibiting the differentiation of cells and 
promoting a more stem-cell like genotype and proliferative phenotype. MSI1 was shown to drive 
the expansion of mammary progenitor cells by upregulating Wnt and Notch signaling [24]. This 
process was mediated by a novel autocrine process involving the MSI1 induced expression of 
PLF and decrease in the Wnt inhibitor, DKK3 and Notch inhibitor, mNUMB.  In this study, they 
found that MSI1 knock-in in mammary epithelial cells increased the abundance of CD24hi/Sca-1+ 
and CD24hi/CD29+ cells, previously identified as breast stem cells. Additionally, MSI1 knock-in 
enhances the expression of genes involved with proliferation, double-stranded DNA break repair, 
cell cycle and cell motility. Although MSI1 knock-in increased the proliferation of mammary 
epithelial cells, it was unable to promote anchorage-independent growth in a 3D culture model, 
suggesting that over expression of MSI1 does not lead to full transformation independently.  
 
Approximately 80% of all colon cancers are associated with a loss of function mutation in the 
tumor suppressor, APC [25].  Loss of APC in the small intestine of mice produces an over 
expression of MSI1 and expansion of undifferentiated cells [26].  Additionally, MSI1 is over 
expressed in APCmin/+ intestinal tumors, suggesting an important function in tumorigenesis, 
downstream of Wnt signaling [27]. Recently, MSI2 was also discovered to be over expressed in 
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APCmin/+ intestinal tumors [7]. Collectively, the studies suggest that both MSI1 and MSI2 are 
involved in the early initiation of colon cancer, downstream of APC and Wnt signaling.   
 
To test if MSI1 acts as a proto-oncogene, the untransformed rat intestinal cell line IEC6 was 
transduced with a lentiviral MSI1 knock-in vector [28]. IEC6-MSI1 mice grew subcutaneous 
xenografts in vivo while the negative control IEC6 cells were unable to grow xenografts in mice.  
The MSI1 induced xenografts expressed high levels of nuclear β-catenin. Additionally, 
xenografts expressed high levels of CCND1 and HES-1; well characterized targets of Wnt and 
Notch signaling [28].  Overall, this study provides evidence that the over expression of MSI1 has 
tumorigenic potential in the colon epithelium, mediated by the upregulation of Wnt and Notch 
signaling.    
 
Using conditional dox-inducible MSI2 knock-in mice, researchers found that MSI2 is involved 
in the transformation of intestinal epithelium [7].  MSI2 knock-in promotes the expansion of 
LGR5+ stem cells and increases crypt height, fission and proliferation. Furthermore, they found 
that MSI2 knock-in mimics the phenotype associated with a loss-of-function APC, suggesting 
that MSI2 is directly involved in the transformation of the epithelium downstream of APC.  
 
MSI2 is highly expressed in the most aggressive form of CML, known as the blast crisis phase 
[29].  In CML mice models, MSI2 is expressed at higher levels than MSI1 and is enriched in 
HSC populations [29].  To understand the role of MSI2 in CML tumorigenesis, researchers 
produced a doxycycline-inducible MSI2 knock-in mouse model [14].  MSI2 knock-in was shown 
to expand the HSC population, but did not induce malignant transformation alone. However, 
when the chronic myeloid leukemia-associated (BCR-ABL) oncoprotein [29] was transduced 
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into the inducible MSI2 cells, mice quickly developed an aggressive form of chronic myeloid 
leukemia as compared to BCR-ABL alone [13, 14].  Furthermore, knocking down MSI2 using 
shRNA induced the differentiation of leukemia cells, inhibited tumor growth and increased 
survival in mice [13].          
 
Collectively, these studies provide evidence that Musashi proteins are directly involved in the 
development of cancer. However, most models highlight the need for a second oncogenic event, 
aside from MSI over expression, in order to fully transform normal cells into malignant cells. 
This is very consistent with the multi-hit hypothesis, suggesting that malignancy results from 
accumulating mutations and oncogenic hits [30].   
 
MSI1 and MSI2: therapeutic targets for anti-cancer therapy 
MSI1 and MSI2 promote tumorigenesis by upregulating Wnt and Notch signaling pathways; two 
attractive signaling cascades for anti-cancer therapy [31].  Multiple studies have shown that 
knocking down MSI1/MSI2 decreases tumorigenesis and prolongs survival in mice. Additionally 
evidence suggests that knocking down MSI1/MSI2 may sensitize cancer cells to chemo/radiation 
therapy.  
 
In xenograft models, MSI1 knock-down reduces tumor growth in breast [10], colon cancer [4], 
medulloblastoma [12], and cervical cancer [18].  Similarly, inhibiting MSI2 was shown to 
decrease tumor growth in leukemia [13], AML [32], and colorectal cancer [7] xenograft models.  




Inhibition of MSI1 and MSI2, individually or together, may provide an advantage for 
overcoming chemo and radiation resistance.  MSI1 is highly expressed in side population (SP) 
cells of the intestinal crypt [33]. SP cells have distinct molecular characteristics and are capable 
of excluding the nuclear stain Hoechst due to the expression of ABC transporters [34].  The 
expression of the ABC transporters are implicated in the ability of stem cells to resist drug-based 
anticancer therapies [33].   
 
MSI1 is overexpressed in both colon and rectal primary tumors [3, 5].  Colorectal tumor cells co-
expressing CD133+/MSI1+ are resistant to Oxiliplatin and 5-flurouracil [35]. Furthermore, crypts 
exposed to toxic levels of 5-flurouracil still express MSI1, suggesting that MSI1+ cells are 
resistant [36].  One study found that inhibiting MSI1 in the colon cancer cell line HCT-116, 
sensitized cells to radiation-induced apoptosis [4].  
 
Knock down of MSI2 sensitized Dami cells (AML cell line) and primary AML cells to 
daunorubicin-induced apoptosis. Daunorubicin is standard therapy for AML patients [32].  The 
blast crisis phase of myeloid leukemia is known to be highly aggressive and less responsive to 
treatment [37].  Since MSI2 is highly expressed in the blast crisis phase in myeloid leukemia 
patients and associated with poor prognosis, inhibiting MSI2 could be a novel therapeutic 
strategy for these patients [13]. 
 
Altogether, MSI1 and MSI2 are promising prognostic and diagnostic biomarkers for a variety of 
cancer types.  Compelling evidence suggests that MSI1/MSI2 inhibition is a promising 
therapeutic strategy for anti-cancer therapy and for possibly overcoming chemo and radiation 
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Stem cell marker, Musashi-1 (MSI1) is over-expressed in many cancer types; however the 
molecular mechanisms involved in MSI1 over-expression are not well understood. We 
investigated the microRNA (miRNA) regulation of MSI1 and the implications this regulation 
plays in colorectal cancer. MicroRNA miR-137 was identified as a MSI1-targeting microRNA by 
immunoblotting and luciferase reporter assays. MSI1 protein was found to be highly expressed in 
79% of primary rectal tumors (n=146), while miR-137 expression was decreased in 84% of the 
rectal tumor tissues (n=68) compared to paired normal mucosal samples. In addition to reduced 
MSI1 protein, exogenous expression of miR-137 inhibited cell growth, colony formation, and 
tumorsphere growth of colon cancer cells. Finally, in vivo studies demonstrated that induction of 
miR-137 can decrease growth of human colon cancer xenografts.  Our results demonstrate that 
miR-137 acts as a tumor-suppressive miRNA in colorectal cancers and negatively regulates 
oncogenic MSI1.  
 
Introduction 
Colorectal cancer (CRC) is the 3rd most common cause of cancer-related deaths for men and 
women in the United States [1]. Worldwide, an estimated 1.4 million people were diagnosed 
with CRC in 2012 [2]. Although, screening methodologies have reduced the incidence of 
patients presenting with late stage disease at diagnosis, treating advanced stage colorectal cancer 
continues to challenge physicians.  We are entering a new era of cancer research which depends 
on understanding the clinicopathological indexes paired with understanding the molecular 
footprint of cancer for improved tailored therapy, recently termed “precision medicine” [3, 4].  
Recent evidence suggests that cancer originates from stem cell-like cells, termed tumor initiating 
cells (TICs) [5, 6].  It is believed that these stem-cell like cells are responsible for cancer 
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initiation and also mediate metastasis and chemoresistance [6]. By gaining insight into the 
mechanisms of these rogue stem cell-like cells, targeted therapies can be designed against TICs.  
 
Recently, a stem cell regulator, Musashi-1 (MSI1), was discovered to be highly expressed in 
colon primary tumors and metastatic lesions in the lymph nodes as compared to paired adjacent 
normal colon mucosal tissue [7].  Furthermore, this study identified MSI1 as a novel prognostic 
biomarker and therapeutic target for treating colon cancer [7].  Knocking down MSI1 in human 
colon cancer cell lines reduces growth, enhances apoptosis after radiation treatment [8] and 
reduces colon cancer proliferation, migration and invasion in vitro [7].   
 
Normally expressed in stem cells, MSI1 is an RNA binding protein which can inhibit translation 
of target mRNAs, including that of APC, NUMB and cyclin-dependent kinase inhibitor/p21WAF-1 
(CDKN1A) [9-11].  MSI1 represses translation by binding to the 3′-UTR of target mRNA, 
therefore inhibiting formation of the 80S ribosome complex [12]. By down-regulating NUMB, 
APC and p21WAF-1, MSI1 positively regulates the Notch and Wnt signaling pathways and 
promotes cell cycle progression [9-11]. Though MSI1 has been identified as a therapeutic target, 
the molecular mechanisms responsible for overexpression of MSI1 in some colorectal cancers 
are not well understood. One possibility is a dysregulation of miRNAs that negatively regulate 
MSI1 mRNA. 
 
miRNAs are short, 20-22 nucleotide, non-coding RNAs that regulate gene expression by binding 
to the 3ʹUTR of target mRNA thereby preventing protein translation or inducing mRNA 
destabilization [13].  miRNAs are predicted to target approximately 60% of all mRNAs, 
therefore, providing substantial regulatory power over many cellular processes [14].  The 
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average 3ʹUTR length of miRNA target genes is approximately 1600 nucleotides, while non-
miRNA target genes average 1000 nucleotides [15]. MSI1 mRNA contains a long 3ʹUTR (~1800 
nucleotides) consistent with possible post-transcriptional regulation by miRNAs. Recently, 
miRNAs negatively regulating MSI1 mRNA were identified and found to be dysregulated in 
glioblastoma [16].  In that study, an initial list of putative MSI1 targeting miRNAs was identified 
using the miRNA prediction program, TargetScan.  Only the candidate miRNAs that had 
previously been reported to have implications in central nervous system tumors were examined 
for the ability to inhibit MSI1. This study provides substantial precedent that miRNAs regulate 
MSI1.  We hypothesized that MSI1-regulating miRNAs are dysregulated in colorectal cancer, 
producing an over expression of MSI1. The objective of this project was to study the post-
transcriptional regulation of MSI1 by miRNAs in colorectal cancer.   
 
In this study, we show that miR-137 directly regulates MSI1. An inverse correlation between 
miR-137 and MSI1 is revealed in a panel of colon cancer cell lines.  Additionally, we found that 
MSI1 protein expression is more abundant in rectal tumors compared to paired adjacent and 
distant normal mucosa.  Alternatively, miR-137 levels are significantly decreased in rectal 
tumors compared to paired adjacent and distant normal mucosa. In vitro studies demonstrated 
that miR-137 over-expression decreases MSI1 expression, reduces cell growth, colony formation 
and tumorsphere growth. The restoration of miR-137 expression in xenograft tumor models also 
reduced tumor growth in vivo. Our work reveals a novel mechanism for MSI1 dysregulation in 







Identification of MSI-targeting miRNAs 
MSI1 mRNA and protein is over-expressed in a panel of colon cancer cell lines compared to 
normal colon cell line, CCD-841 (Figure 1A).  An apparent uncoupling of the mRNA and 
protein levels of MSI1 is revealed in this panel of cell lines, suggesting post-transcriptional 
regulation of MSI1.   The molecular mechanism for MSI1 over-expression in colorectal cancer is 
not well understood.  One possibility is a dysregulation of miRNA regulation.  We utilized three 
miRNA targeting prediction programs (miRanda, TargetScan, PicTar) to identify highly 
conserved putative miRNA binding sites in MSI1 3′UTR.  Using a variety of computational 
algorithms based on seed sequence position, pairing and conservation, these programs predict 
miRNA sites within target genes 3′UTR [17-19].  Among the three prediction programs, five 
overlapping miRNAs contained conserved, potential binding sites within MSI1 3′UTR; miR-
125b, miR-137, miR-144, miR-185, and miR-342-3p (Figure 1B, Appendix Table 1).   
 
In order to determine which miRNAs negatively regulate MSI1 in colon cancer cell lines, 
miRNA mimics and a negative control (NC) mimic were transfected into high-MSI1 expressing 
cell lines; HCT-116 and DLD-1. Exogenous expression of miR-137 reduced MSI1 protein levels 
compared to NC mimic in both HCT-116 and DLD-1 cell lines (Figure 1C).  Interestingly, miR-
125b and miR-342-3p mimics increased the expression of MSI1 in HCT-116 and DLD-1 
respectively, suggesting an alternative mechanism of MSI1 regulation. Although this observation 
is beyond the scope of our current study, future studies focused on the miR-125b and miR-342-
3p regulation of MSI1 may be of interest.  Additional colon cancer cell lines HT29 and HCT-116 
β/W were used to validate our findings, both of which displayed reduced MSI1 protein 




Since MSI1 is overexpressed in the panel of colon cancer cell lines; we hypothesized that miR-
137 is down-regulated. We analyzed the expression of pre and mature-miR-137 in the same 
panel of colon cancer cell lines.  In all five colon cancer cell lines examined, miR-137 expression 
was significantly decreased compared to the normal colon cell line, CCD-841 (Figure 1D). 
Normal human lung fibroblast cell line, WI-38, has similar miR-137 expression levels as the 
normal colon cell line, CCD-841.  As expected, miR-137 and MSI1 expression are inversely 
correlated in cell lines (P = .04, Fisher Exact Test). 
 
miR-137 directly regulates MSI1  
Since miR-137 significantly decreased MSI1 protein expression in both HCT-116 and DLD-1 
compared to the other mimics; we focused this study on understanding the miR-137-mediated 
regulation of MSI1.  miR-137 reduced MSI1 protein expression in a dose-dependent manner 
(Figure 2A).  Furthermore, miR-137 decreased MSI1 mRNA levels more than cells transfected 
with NC mimic (P < .0001) and similarly as cells transfected with MSI1 siRNA (Figure 2B). 
Alternatively, inhibiting endogenous miR-137 in HEK-293FT and HCT-116 using antagomiRs 
increased MSI1 protein expression (Figure 2C and 2D).   
 
Luciferase reporter assays were conducted to determine whether miR-137 inhibits MSI1 via the 
MSI1 3′UTR. HEK-293FT cells were co-transfected with MSI1 3′UTR luciferase reporter 
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Figure 1.  miRNA regulation of MSI1. 
(A)  Expression of MSI1 mRNA and protein analyzed in a panel of colon cancer cell lines using 
quantitative real-time PCR and Western blotting. mRNA normalized to GAPDH and set relative 
to expression in normal colon epithelial cell line, CCD-841.  (B)  Venn diagram displaying 
highly conserved miRNAs predicted to bind to MSI1 3′UTR using miRanda, TargetScan and 
PicTar prediction software.  (C)  MSI1 protein expression analyzed in HCT-116 and DLD-1 
colon cancer cell lines transfected with a panel of miRNA mimics as compared to cells 
transfected with a NC miRNA mimic.  (D)  MSI1 protein expression analyzed in HT29 and 
HCT-116 β/W colon cancer cells lines transfected with miR-137 mimic as compared to cells 
transfected with a NC miRNA mimic.  (E)  Precursor and mature miR-137 expression was 
analyzed in analyzed in a panel of cell lines using qRT-PCR and Taqman PCR.  Pre-miR-137 
was normalized to GAPDH and mature miR-137 expression was normalized to RNU6b. 
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Figure 2.  miR-137 negatively regulates MSI1.   
 
(A)  MSI1 protein expression in HCT-116 cells transfected with increasing concentrations of 
miR-137 mimic as compared to cells transfected with NC mimic.  (B)  Top, MSI1 mRNA and 
protein expression analyzed in HCT-116 cells transfected with NC mimic, miR-137 mimic and 
positive control, MSI1-siRNA. mRNA expression analyzed using qRT-PCR, normalized to 
GAPDH and set relative to NC transfected cells. Bottom, MSI1 protein analyzed using Western 
blotting with β-actin as loading control. (C)  MSI1 protein expression in HEK-293FT cells 
transfected with miR-137 antagomiR (137-Inh.), negative control antagomiR (NC-Inh.), miR-
137 mimic (miR-137), negative control mimic (NC), MSI1 siRNA (si-MSI1) and a negative 
control siRNA (si-NC).  Intensity of MSI1 protein was normalized to β-actin and set relative to 
control. Change in MSI1 protein shown in red.  (D)  MSI1 protein expression in HCT-116 
transfected with NC-Inh, miR-137-Inh, NC-mimic and miR-137 mimic.  (E) HCT-116 cells were 
transfected with wild-type (WT) or mutant (mut) pSGG-MSI1 3′UTR luciferase construct with 




of the MSI1 WT 3′UTR construct (P < .0001), which was de-repressed by mutating the miR-137 
seed sequence within the MSI1 3′UTR (Figure 2E).  Our results confirm that miR-137 negatively 
regulates MSI1 via the MSI1 3′UTR.  
 
miR-137 down-regulates Wnt and Notch signaling  
If miR-137 successfully knocks down MSI1 levels, we would expect an increase in MSI1 target 
genes, p21 and NUMB. As expected, in miR-137-transfected HCT-116 cells, NUMB and p21 
protein expression is increased compared to cells transfected with NC mimic (Figure 3A).  MSI1 
promotes cell growth by positively regulating Notch and Wnt signaling [20], therefore, we 
measured the change in both signaling pathways after miR-137 restoration.  As measured by a β-
catenin reporter (TOP/FOP) assay, miR-137 significantly reduced Wnt signaling in HCT-116 
cells (P < .0001) (Figure 3B).  We also measured Wnt and Notch signaling target genes, C-MYC 
and HES-1, in miR-137- and NC-treated HCT-116 and DLD-1 cells. Both C-MYC and HES-1 
mRNA and protein expression were significantly reduced in miR-137-treated HCT-116 cells 
compared to cells treated with NC mimic (P = 0.0003 and P < .0001) (Figures 3C and 3D). Since 
the MSI1 target, APC is homozygous mutated in DLD-1 cell line and unable to interact with β-
catenin, we expected to see a minimal change in Wnt signaling in this cell line.  Notch signaling 
was reduced in DLD-1 cells, indicated by reduced HES-1 mRNA (P = 0.002) and protein 
expression (Figures 3C and 3D). c-Myc mRNA (P = 0.0325) was slightly reduced in miR-137 
treated DLD-1 cells; however there was no change in C-MYC protein expression in DLD-1 cells 
when treated with miR-137 (Figures 3C and 3D).  Our data suggests that miR-137 reduces Wnt 





























































































































































Figure 3.  miR-137 negatively regulates Notch and Wnt signaling in colon cancer cell lines.   
 
(A)  MSI1, mNumb and p21 protein expression was analyzed in HCT-116 cells transfected with 
miR-137 and NC mimics. (B)  HCT-116 cells were transfected with Top or Fop Flash constructs 
and miR-137 or NC miRNA mimic.  Wnt signaling was stimulated with 20 mM LiCl for 16 h.  
Top Flash luciferase values were normalized to Fop Flash luciferase values.  Data are means ± 
SE; n = 3; **P < 0.01.  (C) mRNA expression of Hes-1 and c-Myc was analyzed in HCT-116 
and DLD-1 cells transfected with miR-137 or NC mimic using qRT-PCR. Expression data was 
normalized to GAPDH and set relative to NC.  Data are means ± SE; n = 3; *** P < 0.001, **P 
< 0.01, *P < 0.05.  (D)  Protein expression of c-Myc and Hes-1 in HCT-116 and DLD-1 cells 
transfected with NC mimic and miR-137 mimics. GAPDH is loading control.  (E)  Tet-on miR-
137 HCT-116 cells were treated with increasing doses of DOX.  Expression of mature miR-137 
was analyzed using Taqman qRT-PCR, normalized to RNU48 and set relative to cells treated 
without DOX.  MSI1, Hes1 and c-Myc mRNA was analyzed using qRT-PCR, normalized to 
GAPDH and set relative to cells treated without DOX. Data are means ± SE; n =3.  (F)  Tet-on 
miR-137 and NC HCT-116 cells were treated with 1 ug/ml DOX for 24, 48 and 72 hours. MSI1 
protein was analyzed using Western blotting. β-actin used as loading control for Westerns.        
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To study the effect of constitutively active miR-137, Tet-inducible miR-137 HCT116 stable cells 
were produced using a pTRIPZ lentiviral expression vector. These stable clones are capable of 
inducing transcription of miR-137 when treated with doxycycline (DOX) to a physiological 
relevant level as compared to the expression of mature miR-137 in colon cell line, CCD-841 
(Appendix Figure S1).  The addition of DOX results in decreased MSI1 expression and 
downstream Notch and Wnt signaling targets, HES1 and C-MYC (Figure 3E).  The decreased 
MSI1 expression is also observed at the protein level (Figure 3F).  In summary, miR-137 
restoration in colon cancer cell lines significantly reduced Wnt and Notch signaling; two 
important oncogenic signaling pathways regulated by MSI1 and involved in colorectal cancer 
progression. 
 
miR-137 acts as a tumor suppressor miRNA in colon cancer 
Based on our preliminary data, we hypothesized that miR-137 acts as a tumor suppressor 
miRNA by negatively regulating MSI1.  To examine the effect of miR-137 restoration on colon 
cancer cells, in vitro cell growth and cell viability assays were utilized.  miR-137 mimic 
transfected HCT-116 cells grew significantly less than cells treated with NC mimic (P < .0001) 
(Figure 4A). To examine whether the miR-137-induced cell growth inhibition was via MSI1 
down-regulation, a phenotype rescue experiment was performed.  miR-137 mediated inhibition 
of cell growth was partially restored when HCT-116 cells were co-transfected with a MSI1 
cDNA expression vector that lacks the 3′UTR as compared to cells co-transfected with an empty 
vector (Figure 4B).  Surprisingly, MSI1 knock-in did not increase the proliferation of HCT-116.  
One possibility is that MSI1 is already highly expressed in this cell line, suggesting that maybe 
too much MSI1 is toxic to the cells, but this needs to be studied in future studies.  Overall, our 
data suggests that miR-137 tumor suppressive function is mediated in part by negatively 
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regulating MSI1.  We also show that cell viability was significantly reduced upon miR-137 













































































































































































Figure 4.  miR-137 inhibits colon cancer growth and clonogenic growth by inhibiting MSI1.  
 
(A) Cell growth curve in HCT-116 cells transfected with miR-137 and NC mimic. Cells were 
collected and counted every day for 4 days.  Data are means ± SE; n = 3; *** P < 0.001.  (B) 
Cell growth curve in HCT-116 cells co-transfected with miR-137/NC mimic and EV-GFP/MSI1-
GFP expression vectors.  Cells were collected and counted every day for 4 days.  Data are means 
± SE; n = 2; **P < 0.01, *** P < 0.001.  (C)  Cell viability was measured using a MTT 
colorimetric assay in HCT-116 cells transfected with miR-137 and NC mimic.  (D)  Colony 
formation assay in HCT-116 and DLD-1 cells transfected with miR-137 and NC mimic. Image 
of representative colonies are shown in right panel.  (E)  Tumorsphere assay in HCT-116 cells 
transfected with miR-137 and NC mimic. Data are means ± SE; n = 3; *** P < 0.001.   (F) 
Colony formation on Tet-on miR-137 cells transfected with MSI1-GFP or EV-GFP constructs. 
Cells were plated in media with and without 1 μg/ml DOX.  Data are means ± SE; n = 2; *P < 





Since MSI1 is a regulator of intestinal multipotent stem cells [21], we predicted that miR-137 
reduces clonogenic cell growth in colon cancer.  miR-137 significantly reduced clonal expansion 
of HCT-116 cells (P < .0001) and DLD-1 (P < .0001), as determined by a colony formation 
assay (Figure 4D). Similarly, tumorsphere growth was also significantly reduced by 
approximately 52% (P = .0006) upon miR-137 restoration in HCT-116 cells (Figure 4E).  Tet-
inducible miR-137 HCT-116 cells were transfected with either a MSI1 cDNA expression 
plasmid or control vector, in the presence or absence of DOX. In non-transfected cells, colonies 
grew significantly less when miR-137 expression was induced using DOX (P = .0055) (Figure 
4E).  However, when cells were transfected with MSI1 cDNA that lacks the 3′UTR, the colony 
formation capability was nearly completely restored (P = .0719) (Figure 4F). 
In summary, miR-137 inhibits clonogenic growth, supporting its predicted role as a tumor 
suppressor miRNA that reduces colon cancer stem cell properties, in part by directly down-
regulating MSI1. 
 
miR-137 reduces tumor growth in vivo 
To study the effect of constitutively active miR-137 expression on tumor progression, HCT-116-
miR-137 tet-on stable clones were subcutaneously injected into flanking sides of athymic nude 
mice.  Ten mice (mean weight = 18.68 g ± 0.563) were randomly separated into two groups. One 
group of mice received 10 mg/ml DOX in the drinking water immediately following injection, 
while the second group of mice did not receive DOX.  The induction of miR-137 decreased 
tumor growth by approximately 75% (n = 8, P = .003, day 33) compared to the tumor growth in 
























































































































































Figure 5.  miR-137 inhibits human colon cancer xenografts growth.   
 
(A)  Tet-on miR-137 HCT-116 cells were injected into subcutaneously into mice. 10 mg/ml 
DOX was administered to the drinking water of one group of mice immediately following 
injections. Average tumor size was calculated at the end of the study and averaged for each 
group (on right).  (B)  Tet-on miR-137 and NC HCT-116 cells were injected into mice. After 
tumors grew to be approximately 50 mm3 in size, both groups of mice were given 1 mg/ml DOX 
in their drinking water.  Average tumor size was calculated at the end of the study and averaged 
for each group (on right).  (C)  MSI1 protein expression was analyzed in three tumor samples 
from Tet-on miR-137 and NC HCT-116 xenograft samples. β-actin was used as loading control. 
(D) Relative mature miR-137 expression and relative MSI1 protein expression in xenografts 




DOX was recently shown to inhibit breast CSCs by reducing energy metabolism and DNA repair 
[22].  To control for DOX’s effect on tumor growth in our studies, a separate animal experiment 
was performed using HCT-116 NC and miR-137 stable cells. Ten mice (mean weight = 22.1 g ± 
0.458) were randomly separated into two groups.  After cells were injected subcutaneously, both 
groups of mice were fed DOX in their drinking water once tumor volumes reached 
approximately 50 mm3.  Similar to the previous animal study, the induction of miR-137 
significantly inhibited colon cancer xenograft tumor growth by 55% (n=10, P < .0001, day 22), 
as compared to mice inoculated with inducible NC mimic (n=10) (Figure 5B).  
 
Tumors were excised at the end of the study to analyze the expression of miR-137 and MSI1. 
The protein expression of MSI1 was decreased in the miR-137-treated tumors as compared to 
NC tumors (P = .0124) (Figure 5C and 5D).  Additionally, miR-137 expression was significantly 
increased in the tet-on miR-137 tumors compared to NC xenografts (P < .0001) (Figure 5D). In 
summary, induction of miR-137 significantly inhibited the human colon cancer xenograft tumor 
growth. Collectively the data supports our hypothesis that miR-137 acts as a tumor suppressor 
miRNA by down-regulating the oncogenic MSI1 that subsequently leads to tumor growth 
inhibition.   
 
Expression of MSI1 and miR-137 in patient tumor samples  
In order to understand the clinical relevance of our study, we used PrognoScan [23], a database 
used to correlate gene expression with patient prognosis, to determine the correlation between 
MSI1 expression with overall survival in patients with a variety of cancer types. Patients with 
high MSI1 expression was significantly correlated with an increased hazards risk for poor overall 
survival in patients with bladder cancer (n = 165, P = 0.0150), AML (n = 34, P = 0.0002), 
colorectal cancer (n = 55, P = 0.0151) and ovarian cancer (n = 133, P = 0.0019) (Figures 6A). In 
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the colorectal dataset (GSE17537), high MSI1 significantly correlates with increased hazard risk, 
analyzed using a Kaplan-Meier curve and Cox proportional hazards regression test (Figure 6B).   
 
We also examined the expression of MSI1 and miR-137 in available tissue samples from patients 
with rectal cancer.  MSI1 protein expression was analyzed using immunohistochemistry in 
distant normal mucosa, adjacent normal mucosa, primary tumor and lymph node metastasis 
tissue samples collected from patients with rectal cancer (Figure 6C). The average score for 
MSI1 intensity was significantly higher in tumor samples collected from primary tumor (P < 
.0001) and metastatic lesions (P < .0001) (Appendix Table 3) as compared to distant normal and 
adjacent normal mucosal tissue samples. For analysis, samples were categorized into high MSI1 
expressing with intensity scores greater than two, while scores equal to or less than two were 
defined as low MSI1 expressing.  MSI1 was highly expressed in 79% of primary tumor samples, 
and 53% of metastatic lesion samples. Inversely, MSI1 was highly expressed in 1% of distant 
normal samples and 8% of adjacent normal samples (Figure 6D and Appendix Table 4).   
 
The expression of miR-137 was measured in 68 paired normal mucosal and primary tumor tissue 
samples using Taqman qRT-PCR.  miR-137 was significantly decreased in 84% of primary 
tumor tissue samples when compared to the paired adjacent normal tissues (n = 68, P < .0001) 
(Figure 6E and Appendix Table 5).  The expression of miR-137 did not statistically correlate 
with MSI1 expression in tissue samples (P = 0.54, Appendix Table 6), although a clear trend is 
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Figure 6.  Musashi-1 is over expressed and miR-137 is decreased in rectal cancer tissue 
samples.   
 
(A) Expression of MSI1 in a variety of cancer types is correlated with survival using PrognoScan 
database. (B) Kaplan-Meier curve associated with the colorectal dataset GSE17537. High MSI1 
correlates with poor overall survival. Analyzed using PrognoScan database, Log-rank test, P = 
0.0151.  (C)  Representative images of MSI1 immunohistochemistry in distant normal rectal 
mucosal tissues (left panel) and rectal primary tumor tissue (right panel). Bar = 5 μm. 
Magnification: 40x.  (D)  MSI1 intensity scores were categorized into low expressing (TMA 
scores of 0+1+2) and high expressing (TMA scores of 3). The percentage of low and high MSI1 
expression was calculated for each tissue type.  (E)  Mature miR-137 expression was analyzed in 
68 pairs of normal and primary rectal tumor tissues using Taqman PCR.  miR-137 was 
normalized to RNU6b and set relative to matching normal. *** P < 0.001.  (F) The overall 
survival of 93 patients was analyzed comparing decreased and increased expression of miR-137 




patients for the expression of MSI1 and miR-137 is needed in order to obtain statistical 
significance.  Correlating miR-137 expression with patient survival demonstrated that patients 
with decreased miR-137 had an increased hazard of death (HR = 0.61) as compared to patients 
with no change or increased expression of miR-137, although this did not reach statistical 
significance (P = .269) (Figure 6F).  In conclusion, our results show that miR-137 expression is 
decreased in colon cancer cell lines and rectal cancer tissues, and supports our overall hypothesis 
that loss of miR-137 promotes the overexpression of MSI1 in colorectal cancer.  
 
Discussion 
 In the current study, we show that miR-137 can regulate MSI1 in colon cancer cell lines. We 
revealed an inverse correlation between miR-137 and MSI1 in a panel of colon cancer cell lines 
as compared to a normal epithelial cell line, and in primary rectal tumor tissues as compared to 
paired normal rectal mucosal tissue. miR-137 restoration in colon cancer cell lines, reduces 
MSI1 mRNA and protein levels, and inhibits cell growth, colony formation and tumorsphere 
growth.  Furthermore, expressing miR-137 in HCT-116 significantly reduces xenografts tumor 
growth.  In conclusion, our data suggest that miR-137 acts as a tumor suppressive miRNA and 
when down-regulated promotes tumorigenesis through the up regulation of MSI1.    
  
Multiple studies have found an overexpression of MSI1 in a broad range of cancer types, 
including breast cancer, lung and colon cancer [7, 8, 24, 25].  We are the first to report an 
overexpression of MSI1 specifically in rectal cancer in a large patient cohort.  Although colon 
and rectal cancer are often grouped together under the category of colorectal cancer, their 
treatment strategies differ significantly.  For colon cancer, typically surgical resection combined 
with chemotherapy is the primary treatment strategy [26].  For rectal cancer, radiation therapy 
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combined with surgical resection is commonly used [26].   Previous studies have found that 
MSI1 knockdown sensitizes colon cancer cells to radiation therapy [8].  Collectively, this 
suggests that future therapeutic strategies targeting MSI1 may be relevant for both colon and 
rectal cancer patients and possibly in combination with conventional treatment strategies, such 
radiation therapy.  We hope to address these possibilities in future studies.   
  
One aim of our study was to understand why MSI1 is overexpressed in colorectal cancer.  As 
shown in the small intestine and colon tissue of adult and developing mice, MSI1 is 
predominately expressed in the base of crypts and less so towards the top of the transit 
amplifying region of the crypt, before reaching the villus location.[21]  Stem cell genes are often 
tightly regulated by miRNAs upon differentiation [27, 28].  We propose that a lack of miRNA 
regulation during proliferation and subsequent differentiation of colon stem cell progeny causes 
MSI1 overexpression in colorectal cancer. The purpose of this study was to identify miRNAs 
capable of negatively regulating MSI1 in hopes of learning more about the potential cause of 
MSI1 overexpression in colorectal cancer.  We successfully identified miR-137 as a negative 
regulator of MSI1 in colon cancer cells. Our findings are consistent with a previous study that 
discovered miR-137 as a negative regulator of MSI1 in a glioblastoma cell model [16].  
  
Taken together, the data suggests that in normal cells, MSI1 is negatively regulated by miR-137, 
possibly during differentiation, and this level of regulation has been dismantled in colorectal 
cancer cells, thus leading to the MSI1 overexpression.  Previous studies have shown that miR-
137 expression increases upon differentiation of neural stem cells [29, 30] and mouse embryonic 
stem cells [31].  In cancer, miR-137 has been shown to be decreased in glioblastoma [30, 32], 
melanoma [33], gastric cancer [34], and colorectal cancer [35-37].   
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 According to our results, loss of miR-137 appears to be at the transcriptional level since both pre 
and mature forms of miR-137 were decreased in colon cancer cell lines. Our data is consistent 
with previous studies that discovered loss of miR-137 occurs early in the progression of colon 
cancer due to hypermethylation of the promoter region [35], which prevents binding of the 
transcription factor, high-mobility group AT-hook (HMGA)1 [37]. This observation strongly 
supports our results and overall hypothesis that in colon cancer, miR-137 expression is silenced 
during differentiation due to hypermethylation, resulting in MSI1 over-expression. However this 
specific mechanism needs to be studied further.  
 
Overall, we describe an important tumor-suppressive mechanism of miR-137 through the 
negative regulation of MSI1 and Notch/Wnt signaling, outlined in our working model (Figure 7).  
miR-137 is a promising candidate for future miRNA-based molecular therapy for treating a 
variety of cancer types, including colorectal cancer. Our findings provide insight into the 
mechanism of dysregulation of colon cancer stem cells and eventually colorectal cancer initiation 
and progression. By understanding the molecular mechanisms of colorectal cancer biology, 































Figure 7. Working model. 
 
RNA binding protein and stem cell regulator, MSI1, positively regulates the Wnt and Notch 
signaling pathways by binding to and inhibiting the translation of target mRNA; APC, p21WAF-1, 
and NUMB.  In this study, we show that miR-137 acts as a tumor suppressive microRNA, in part 




Material and methods 
 
Patient Samples and Tissue Microarray 
Tissue microarray (TMA) slides were prepared from formalin-fixed paraffin embedded tissue 
blocks and contained tissue specimens from 146 primary rectal adenocarcinoma samples, 116 
distant normal mucosa samples, 80 adjacent normal mucosa specimens, and 49 lymph node 
metastases.  Tissue samples were collected from patients enrolled in a randomized clinical trial 
testing preoperative radiation therapy in the Southeast region of Sweden [38].  Distant normal 
mucosa was taken from proximal or distal margin (4-35 cm from the primary tumor) of the 
resected rectum and adjacent normal mucosa was taken from the mucosa tissue adjacent to the 
primary tumor.  Both normal sections were histologically free from tumor.  Additional details 
regarding the patient cohort and tumor characteristics are presented in Appendix Table 2. Each 
patient was provided detailed information about the study aims and protocol, and gave their 
written informed consent prior to enrollment. The study was approved by the Institutional 
Review Board of the Linköping University, Sweden. 
  
PrognoScan Analysis 
The correlation between MSI1 expression and patient prognosis was evaluated using the 
PrognoScan database (http://www.abren.net/PrognoScan/) [23].  Using the minimum P-value 
approach, patients samples are grouped into high and low MSI1 expressing groups and correlated 
with survival using a Kaplan-Meier curve and log-rank test.  Hazard risk is tested using a cox 






Immunohistochemistry of TMA 
Immunohistochemistry was performed on TMA slides according to our previous publication 
[39].  Anti-Musashi-1 rabbit monoclonal antibody was used at a dilution of 1:50 (EMD 
Millipore, Billerica, MA, United States).  A negative control experiment was performed using 
tissue samples from primary rectal cancer, incubated with PBS rather than anti-Musashi-1 
primary antibody and probed with secondary anti-rabbit antibody to detect background signal 
produced by the secondary antibody (data not shown).  The specificity of the anti-MSI1 antibody 
(Millipore, 04-1041) was tested in HEK-293FT cells treated with a MSI1-siRNA and NC-siRNA 
using Western blotting (data not shown). Specific details of the reagents and material used for 
this study are outlined in Appendix Table 7.      
 
Since MSI1 was homogeneously expressed in the epithelial cells among the tumor tissue 
sections, only MSI1 intensity was scored. Scoring was performed by two trained scientists 
independently without knowledge of clinicopathological information and reviewed by a 
pathologist. Each tissue sample had three replicate tissue cores included in the TMA. The highest 
TMA score for the three replicates was used as a representative score and the average intensity 
score between the two independent scorers was used as a final representative TMA score for 
each tissue sample.  Scoring was based on MSI1 intensity: scores 0 displayed no visible MSI1 
staining (negative), scores 1, 2 and 3 were weak, moderate and strong MSI1 staining.   
 
Taqman microRNA Analysis in Patient Tissue Samples 
MicroRNA was isolated from paraffin-embedded tissue sections from rectal cancer patients 
using RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Life Technologies, Stockholm, 
Sweden). The microRNA quality was assessed by studying amplification efficiencies of 
75 
 
microRNAs after serial dilutions of cDNA and measuring CT values of microRNAs using real 
time PCR.  miR-137 expression was determined using Taqman microRNA assay and normalized 
to control small RNA, RNU6b.  The expression of miR-137 in the tumor samples was 
normalized to RNU6b and set relative to the expression of miR-137 in normal mucosal samples.   
 
Cell Culture and Reagents  
The following cell lines were purchased from American Type Culture Collection (ATCC, 
Manassas, VA, United States); HCT-116, DLD-1, SW480, HT29, 293 FT, 293 WT, CCD-841 
CoN and passaged according to ATCC protocol.  HCT-116 β/W cell line was a generous gift 
from Bert Vogelstein (The Johns Hopkins University School of Medicine) [40]. Cells were 
cultured in Dulbecco’s modified Eagle medium (Sigma-Aldrich, St. Louis, MO, United States), 
supplemented with 10% fetal bovine serum (GE Healthcare HyClone, Logan, Utah, United 
States), and 1% Penicillin-Streptomycin antibiotic (Life Technologies, Grand Island, NY, United 
States).   
 
In Vitro Studies 
miRNA mimics, siRNAs, NC mimics, NC siRNA, miR-137 antagomiR and antagomiR-NC were 
purchased from Dharmacon (GE Dharmacon, Lafayette, CO, United States).  Transfections were 
carried out as previously described [41].  Briefly, cells plated in a 6-well plate were transfected 
with 100 pmol (50nM) miRNA mimics, siRNAs or antagomiRs using Lipofectamine 2000 
(Invitrogen, Life Technologies).  For cell growth assays, HCT-116 cells were transfected with 
miR-137 mimic and negative control (NC) mimic and re-seeded 24 hours later in a 24-well plate.  
Cells were collected every day for 4 days and living cells were counted using trypan blue 
staining and a hemocytometer as previously described [42].  For the cell growth rescue 
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experiment, cells were co-transfected with miR-137 and NC mimics (50nM) and the MSI1-
GFP/EV-GFP expressing constructs (1 µg) for 24 hours and re-seeded in a 24-well plate.  Cells 
were collected and counted as described above every day, for 4 days.  Cell viability of cells was 
determined using a MTT colorimetric assay. Briefly, cells were transfected with miR-137 and 
NC mimics, 24 hours later cells were re-seeded into a 96-well plate in triplicate. After 4-6 days 
(or until ~90% confluency of NC group), cell medium was replaced with WST-8 (Sigma) dye for 
1-5 hours.  The absorbance was quantified using a microplate reader (BioTek, Winooski, VT, 
United States) at 450 nm. The absorbance of miR-137-treated cells was set relative to cells 
treated with NC mimic.  
 
Western Blot Analysis 
After 48-72 hours of transfection with mimics, antagomiRs, or siRNAs, cells were collected for 
Western blotting as previously described [43].  Antibodies used for our studies are detailed in 
Appendix Table 7.  
 
Luciferase Reporter Assays 
The pSGG-MSI1 3′UTR luciferase construct was a gift from Luiz O.F. Penalva and previously 
described [44].  Cells were transfected with 200 ng of pSGG-MSI1 3′UTR luciferase construct 
and 20 nM miR-137 mimic or NC mimic using Lipofectamine 2000. Three nucleotides within 
the miR-137 seed sequence in the pSGG-MSI1-3′UTR construct were mutated using the 
QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA, United States). After 48 
hours, cells were harvested and assayed using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, United States). Wnt signaling was measured using the TOP/FOP Flash 
reporter constructs (Millipore).  Cells were transfected with 200 ng of TOP or FOP Flash 
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constructs and 20 nM miR-137 mimic or NC mimic using Lipofectamine 2000. Transfected cells 
were stimulated with 20 mM LiCl for 16 hours prior to harvest at 48 hours post-transfection.  A 
renilla luciferase construct was used as a normalizing control for all luciferase assays. 
Experiments were conducted in triplicate. 
 
Quantitative Real-Time PCR 
Quantitative real-time PCR was performed using gene specific primers (Appendix Table 8), 
SYBR® Select master mix (Applied Biosystems, Life Technologies) and normalized to GAPDH. 
The expression of mature miR-137 was quantified using microRNA TaqMan® Assays (Life 
Technologies) and normalized to housekeeping small RNAs, RNU6b or RNU48 (Appendix 
Table 7).  Expression of genes were normalized using the equation 2-ΔCt = 2-(Ct (housekeeping gene) – Ct 
(gene of interest)) [45]. 
 
Colony Formation and Tumorsphere Assay 
Colony formation assays were performed using HCT-116 cells transfected with 100 pmol 
mimics (miR-137 and NC) in a 6-well plate for 24 hours and then re-seeded (300 cells/well) in a 
6-well plate in triplicate according to our previous publication [41].  For the tumorsphere assay, 
HCT-116 cells were transfected as described above and re-seeded into 24-well ultra-low 
attachment plates in triplicate at 2000 cells per well according to our previous publication [46].  
The number of colonies and tumorspheres grown in miR-137 treated cells was set relative to the 
number of tumorspheres grown in NC treated cells.  A rescue experiment was performed using a 
colony formation assay and a pCMV6-MSI1-GFP construct purchased from Origene (Rockville, 
MD, United States). A pCMV6-EV-GFP construct was produced by removing the MSI1 coding 
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sequence from Sgf1/Xho1 sites and replacing it with a 24 base pair linker; 5′-
TCACAACCTCCTAGAAAGAGTAGA-3′.   
 
Production of Tet-on HCT-116 Stable cell lines 
The mature miR-137 or NC mimic sequence was cloned into the Tet-inducible pTRIPZ 
expression vector (Dharmacon) according to manufacturer’s instructions. Stable cell lines were 
generated by lentiviral transduction of HCT-116 cells and selected with 1.2 µg/ml puromycin for 
1 week.  Cells were treated with 0.25, 0.5 or 1 μg/ml of doxycycline (DOX) to induce the 
transcription of miR-137 in HCT-116. 
 
Animal Studies  
Animal experiments were done according to the Institutional Animal Care and Use Committee 
(IACUC) protocol approved by the University of Kansas Guidelines for Use and Care of 
Animals.  HCT-116 stable clones with inducible miR-137 and NC miRNA were injected (0.5 x 
106) into sub-cutaneous regions 5-6 week old, female athymic nude mice (Hsd:Athymic Nude-
Foxn1nu, Harlan). Mice were separated into control and experimental groups randomly 
(N=5/group) for each animal study. In the tumor progression experiment, after the tumors 
reached approximately 50 mm3 in size, mice were fed 1 mg/ml Doxycycline Hyclate (Sigma) in 
the drinking water to induce the expression of miR-137 or NC miRNA. In the tumor initiation 
study, DOX (1 mg/ml) was administered immediately after cell injections. Tumor growth was 
measured using calipers, 2-3 times per week. To avoid biased interpretations, scientists 
measuring tumor volume were unaware of treatment groups. Tumor volume was calculated using 





Chi-square test was used to examine the significance of the differences in MSI1 expression in 
distant or adjacent normal mucosa, primary cancer and lymph node metastasis, as well as the 
correlation of MSI1 expression and miR-137 expression with clinicopathological variables.  
miR-137 expression with overall survival was tested using Log-Rank and Cox proportional 
hazards regression analysis. Survival curves were computed according to Kaplan-Meier 
estimates.  Two-way ANOVA test was utilized to study the significance of the cell growth curve 
and xenograft tumor growth studies.  All tests were two sided and a P-value (P) of < .05 was 
considered statistically significant. Data represent average results from at least three independent 
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The RNA binding protein, Musashi-2 has been identified as a critical regulator for hematopoietic 
stem cell (HSC) maintenance, specifically by negatively regulating NUMB [1, 2].  When 
overexpressed, MSI2 impairs the ability of HSC to differentiate into mature blood cells [1].   The 
over expression of MSI2 has been identified in multiple cancer types and is most commonly 
studied in cancers of the blood [1, 3, 4].  However, the function and expression of MSI2 in solid 
tumors has not been extensively studied. Recently, MSI2 was shown to be overexpressed in 
colorectal cancer and identified as a driver of transformation in the intestinal epithelium [5].  
Although the expression of MSI2 and its oncogenic nature has been studied in multiple cancer 
types, the regulation of MSI2 remains largely under studied.   
 
We recently identified miR-137 as a tumor suppressor microRNA, in part by negatively 
regulating Musashi-1 [6].  Additionally, we discovered that miR-137 was significantly decreased 
in rectal tumor samples as compared to adjacent normal mucosa tissues.  Musashi proteins share 
similar RNA binding domains and are thought to be functionally redundant [7]. Therefore, we 
speculated that miR-137 negatively regulates both Musashi RNA-binding proteins.  
 
In this study, we identified a miR-137 seed sequence in exon 12 of MSI2 coding sequence.  
Exogenous miR-137 negatively regulates MSI2 in colon and breast cancer cell lines. Inhibiting 
endogenous miR-137 in normal colon cells, kidney fibroblast, and rat intestinal epithelial cells 
increases the expression of MSI2 mRNA and protein.  We are the first to report the 





In conclusion, our study provides preliminary evidence that MSI2 is a novel target of miR-137 
mediated by a non-canonical mechanism. Our study suggests that miR-137 may play an 
important role in the differentiation of breast and colon stem cells by negatively regulating the 
stem cell regulators and RNA-binding proteins, MSI1 and MSI2.  
 
Results 
Musashi-2 is overexpressed in breast and colon cancer cell lines 
We first set out to characterize the expression of MSI2 in breast and colon cancer cell lines.  In a 
recent study, MSI2 was found to be highly expressed in colorectal cancer, however that study did 
not measure the expression of MSI2 in cell lines [5].  We recently published a paper in 
Oncotarget showing that miR-137 was significantly downregulated in colorectal cancer and 
colon cancer cell lines [6]. To our knowledge, the expression of MSI2 in breast cancer has not 
been reported. A previous study reported a significant decrease in miR-137 expression in cell 
lines; MCF-7, T47D SKBR-3, BT-474 and MDA-MB-231 as compared to breast epithelial cell 
line MCF-10a [8].   
 
We characterized the expression of MSI2 and miR-137 in a panel of breast and colon cancer cell 
lines.  In breast cancer cell lines, the expression level of MSI2 mRNA was set relative to 
expression of MSI2 in HMEC, a primary mammary epithelial cell line. Multiple non-tumorigenic 
breast cell lines were included in the study to serve as additional controls; MCF-10a, MCF-12a 
and MCF-15a.  Out of the 13 breast cancer cell lines, 9 (69%) had overexpressed MSI2 mRNA 
and 8 (62%) had overexpressed MSI2 protein (Figure 1A and 1C).  To our knowledge, this is the 
first study to show that MSI2 is overexpressed in breast cancer.  Our results are consistent with a 
previous study that showed that miR-137 is decreased in multiple breast cancer cell lines (Figure 
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1B) [8].  Our study expands upon the current knowledge by including expression data for miR-
137 in a larger panel of breast cancer cell lines.  Interestingly, not every cell line had low miR-
137, suggesting that the mechanism for controlling miR-137 expression is heterogeneous in 
breast cancer, such as DNA methylation [9, 10].  
 
In the panel of colon cancer cell lines, MSI2 mRNA was slightly overexpressed in multiple cell 
lines as compared to the expression of MSI2 in the normal colon cell line, CCD-841.  Inversely, 
miR-137 was negatively regulated in all colon cancer cell lines tested (Figure 1D). We measured 
the expression of the precursor and mature form of miR-137 to assess the processing efficiency 
of miR-137. With the exception of 293FT, the transcription of miR-137 appears to be inhibited. 
This observation is consistent with previous observations that mR-137 in silenced in colon 
cancer due to hypermethylation of its promoter [9].  The expression of MSI2 protein in the panel 
of colon cancer lines needs to be analyzed in future studies.  
 
Exon 12 of Musashi-2 contains a single miR-137 seed sequence 
In previous studies, we found that Musashi-1, the sister protein for Musashi-2, is negatively 
regulated by miR-137 [6].  Since the RNA binding proteins have been shown to be functionally 
redundant, we wondered if miR-137 negatively regulates both Musashi proteins. A seed 
sequence for miR-137 was not found in the 3ʹUTR of MSI2 using a variety of miRNA prediction 
programs such as TargetScan, miRanda and PicTar [11-13].  However, using DIANA microT-
CDS miRNA prediction program [14], a miRNA prediction program that will identify predicted 
miRNA seed sequences in the 3′UTR and coding sequence (CDS) of target mRNA, a single 
miR-137 putative binding site was found within exon 12 of MSI2 coding region (Figure 2A).  
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miR-137 is predicted to bind between nucleotides 358-386 of the MSI2-CDS-3′UTR sequence; 
corresponding to nucleotides 531-559 of the full length sequence of MSI2 (5′UTR-CDS-3′UTR).   
 
Additionally, we used the MIRZA-G program to predict the interaction between miR-137 and 
MSI2 based upon the predicted secondary structure of target mRNA, the accessibility of the 
miRNA seed sequence and the biophysical properties [15]. This program predicted that a binding 
event between MSI2 and miR-137 was most likely located between nucleotides 531-559 of 
MSI2-CDS (Figure 2B).  This binding site corresponds to the predicted miR-137 seed sequence 
predicted by DIANA microT-CDS program, thus providing additional evidence that miR-137 



























Figure 1.  MSI2 is overexpressed in breast and colon cancer cell lines.   
(A)  MSI2 mRNA was measured in a panel of breast cancer cell lines, normalized to GAPDH 
and set relative to the primary human mammary epithelial cell line (HMEC).  (B) The expression 
of mature miR-137 was measured using Taqman qRT-PCR, normalized using RNU48 and set 
relative to HMEC.  (C)  MSI2 protein expression was measured using Western blotting. The 
expression of MSI2 was normalized to β-actin and set relative to HMEC (values displayed in 
red).  (D) The expression of precursor/mature miR-137 and MSI2 mRNA was measured in a 
panel of colon cancer cell lines using qRT-PCR and Taqman qRT-PCR, normalized to RNU6b 
and GAPDH and set relative to normal colon epithelial cell line CCD-841.      
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Figure 2.  miR-137 contains a seed sequence within exon 12 of Musashi-2 
(A) A seed sequence for miR-137 was identified in exon 12 of MSI2 using DIANA microT-CDS 
program. (B)  The location of miR-137 binding sequence is predicted based on biophysical 




Exogenous miR-137 negatively regulates Musashi-2 in multiple breast and colon 
cancer cell lines 
To determine if miR-137 negatively regulates MSI2 expression, miR-137 mimic (137-m), 
negative control (NC-m), negative control siRNA (NC-si) and positive control MSI2-siRNA 
(MSI2-si) were transfected into high MSI2 expressing colon and breast cancer cell lines; HT29, 
DLD-1, MCF-7 and SUM-159.  Exogenous expression of miR-137 negatively regulated MSI2 
protein in all four cell lines (Figure 3). Interestingly, in colon cancer cell lines HT29 and DLD-
1, miR-137 knock-in reduced the expression of MSI2 mRNA (Figure 3A and 3B), but not in 
breast cancer cell lines MCF-7 and SUM-159 (Figure 3C). Our data suggests that in colon 
cancer cell lines, miR-137 promotes the degradation/destabilization of MSI2 mRNA, whereas in 
breast cancer cell lines, miR-137 only prevents the protein translation of MSI2. The difference 
between these two mechanisms of miR-137 mediated regulation of MSI2 needs to be studied in 
future studies. 
 
Knockdown of miR-137 increases Musashi-2 in multiple cell lines 
 Colon cell line, CCD-841, was transfected with a miR-137 antagomiR, an inhibitor of mature 
miR-137 (137-I). The expression of MSI2 was measured using qRT-PCR and Western blotting. 
Knocking down miR-137 increased the expression of MSI1 and MSI2 mRNA as compared to a 
negative control antagomiR (NC-I) (Figure 4A), however, only MSI2 protein expression was 
significantly increased (Figure 4B and 4C).  In this cell line, MSI2 is more highly expressed 
than MSI1, suggesting that MSI2 is more transcriptionally activated. This may explain why the 
change in protein level is more easily observed for MSI2 rather than MSI1. This experiment was 
repeated in HEK-293WT and RIE cells. In both cell lines, knocking down miR-137 (Figure 4D) 
increased MSI2 protein (Figure 4D). Inversely, knocking in miR-137 decreased MSI2 in both 
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Figure 3.  Exogenous miR-137 negatively regulates MSI2 in colon and breast cancer cell 
lines.  
MSI2 mRNA and protein expression was measured in colon cancer cell lines HT29 (A) and 
DLD-1 (B) hours after transfection with microRNA mimics and siRNAs. (C)  MSI1 and MSI2 
mRNA was measured in transfected MCF-7 and SUM-159 breast cancer cell lines. (D) MSI2 
protein expression in MCF-7 and SUM-159 after transfection with mimics and siRNAs. β-actin 
was used as loading control for Western blots. The expression of MSI1 and MSI2 mRNA was 
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Figure 4.  Knock-down of endogenous miR-137 increases MSI2 in multiple cell lines 
(A) Expression of mature miR-137, MSI2 and MSI1 mRNA in CCD-841 cells transfected with a 
negative control inhibitor (NC-I) and a miR-137-inhibitor (137-I). miR-137 was normalized to 
RNU48 and MSI1/MSI2 mRNA was normalized to GAPDH and set relative to NC-I. (B) 
Expression of MSI1 and MSI2 protein in transfected CCD-841. (C) The relative expression of 
MSI1 and MSI2 in transfected CCD-841 from multiple experiments. Data is normalized to β-
actin and set relative to NC-I control. (D) Expression of mature miR-137 in transfected 
HEK29WT and RIE cells. Data is normalized to RNU6b and set relative to appropriate control. 
(E) Expression of MSI2 protein in transfected HEK293WT and RIE cells. Β-actin is used as 





miR-137 directly regulates Musashi-2 
To understand if miR-137 directly regulates MSI2 by binding to the coding sequence of MSI2, 
we utilized a cmv-MSI2 cDNA expression vector (does not contain a 3ʹUTR) for transfections.  
Kidney fibroblast cells (HEK293WT) and rat intestinal epithelial cells (RIE) were co-transfected 
with a cmv-empty vector/cmv-MSI2 vector with NC-mimic and 137-mimic.  MSI2 mRNA was 
measured 72 hours after transfections using qRT-PCR.  Consistently, exogenous miR-137 
negatively inhibits endogenous MSI2 mRNA (Figure 5a).  Additionally, we saw a significant 
decrease in the expression of cmv-MSI2 mRNA in HEK293WT cells co-transfected with miR-
137-mimic as compared to cells co-transfected with cmv-MSI2 and NC-mimic (Figure 5a).  This 
data suggests that miR-137 inhibits MSI2 by directly binding to MSI2-CDS.  
 
Interestingly, miR-137 knock-in does not inhibit the expression of endogenous MSI2 mRNA in 
RIE cells (Figure 5b), although we previously showed that miR-137 negatively regulates MSI2 
protein in RIE (Figure 4E).  The miR-137 seed sequence is nearly perfect conserved between rats 
and humans, with only 1 nucleotide difference, and is predicted to be involved in the 
complementary base pairing between miR-137 and MSI2 mRNA.  This suggests that this 1 
nucleotide directly influences the miR-137 mediated regulation on MSI2.  When co-transfected 
with cmv-MSI2 and miR-137 mimic in RIE cells, MSI2 mRNA was significantly decreased as 
compared to cells co-transfected with cmv-MSI2 and NC-mimic (Figure 5b).  Overall, our data 
suggests that miR-137 directly inhibits MSI2 expression; however, the mechanism of the 





































































































































Figure 5. Exogenous miR-137 inhibits exogenous MSI2 in HEK-293WT and RIE cells.  
Expression of MSI2 mRNA in HEK-293WT cells (A) and RIE cells (B).  Data was normalized to 







RNA binding protein MSI2 has been well studied in hematopoietic cancers and is well known 
for its oncogenic function and maintenance of leukemia stem cells [1, 16]. The function of MSI2 
in solid tumors is vastly understudied. One recent study found that MSI2 was overexpressed in 
colorectal tumor samples as compared to adjacent tissues [5]. Furthermore, they found that 
doxycycline-inducible MSI2 knock-in lead to an expansion of the LGR5+ stem cells, 
proliferation, crypt fission and growth, and overall encouraged transformation of the intestinal 
epithelium. The mechanism associated with MSI2 overexpression in colorectal cancer has not 
been studied.  
 
Our study is the first to report an overexpression of MSI2 in breast cancer cell lines. 
Interestingly, when comparing the expression of MSI2 with the molecular subtype of breast 
cancer, we discovered that all estrogen receptor (ER+) and progesterone receptor (PR+) breast 
cancer cell lines had high expression of MSI2 and low expression of miR-137.  However, not all 
high-MSI2 expressing cells were ER+ and PR+.  Out of the 7 luminal breast cancer cell types, 5 
of the luminal cell lines had high expression of MSI2.  Our data suggests that MSI2 expression 
may correlate with ER+/PR+ breast cancer from luminal origin, but needs to be studied further. 
Additionally, characterizing the expression of MSI2 and miR-137 in clinical breast cancer tumor 
samples would provide a great deal of value.  
 
We recently discovered that miR-137 is a negative regulator of MSI1 and is lost in colon cancer 
cell lines and rectal tumor tissue samples as compared to adjacent normal mucosal tissue [6].  
miR-137 restoration decreased the mRNA and protein expression of MSI1. Since MSI1 and 
98 
 
MSI2 have been shown to work in redundant pathways, we wondered if miR-137 was capable of 
negatively regulating both Musashi proteins. 
 
In this study, we discovered that MSI2 contains a single seed sequence for miR-137 in exon 12 of 
its coding sequence. Restoration of miR-137 in colon and breast cancer cell lines reduced the 
protein expression of MSI2.  Additionally, exogenous miR-137 negatively regulates the 
expression of a cmv-MSI2 cDNA vector, suggesting that miR-137 directly inhibits MSI2.  
Future miR-137 seed sequence mutational studies would provide additional evidence of the 
direct binding event and the specific location of the miR-137 seed sequence within MSI2 CDS.  
 
Although miR-137 appears to negatively regulate both Musashi proteins, the mechanism by 
which miR-137 regulates these sister proteins may be entirely different.  In breast cancer cell 
lines MCF-7 and SUM-159, exogenous miR-137 reduces the amount of MSI1 mRNA in cells, 
but not MSI2 mRNA, even though MSI2 protein was knocked-down after 72 hours. This data 
suggests that miR-137 promotes the cleavage of MSI1 mRNA, but not MSI2 in breast cancer. In 
colon cancer cell lines HT29 and DLD-1, exogenous miR-137 reduces MSI2 mRNA and protein, 
suggesting that the miR-137 mediated regulation of MSI2 is a very dynamic mechanism across 
cell types. More studies are needed to tease out the different miR-137-mediated regulation of 
MSI1/MSI2.   
 
Altogether, our data provides evidence that miR-137 negatively regulates both RNA-binding 
proteins Musashi-1 and Musashi-2. Our findings may provide an explanation for the 
overexpression of MSI1 and MSI2 in colorectal and breast cancer [5, 6, 17, 18], although 
additional studies need to be carried out.  
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Materials and methods 
 
Cell Lines and Reagents  
Cell lines used for the studies were purchased from American Type Culture Collection (ATCC) 
and cultured according to their recommendations.  Rat intestinal epithelial (RIE) cells were a 
kind gift from Dr. Kristi Neufeld (University of Kansas).  
 
MicroRNA Target Prediction 
DIANA-microT-CDS is a microRNA target prediction program that predicts miRNA seed 
sequences within the 5′UTR, coding sequence and 3′UTR [14].  MIRZA-G predicts canonical 
and non-canonical miRNA binding sites, along with siRNA off-target sites [15]. This program 
considers the biophysical interaction between miRNA and target mRNA, such as the nucleotide 
composition surrounding the miRNA seed sequence, the predicted secondary structure of the 
target RNA, the accessibility of the miRNA target site and the location within the 3′UTR.  
 
In Vitro Studies 
Reagents used for the in vitro studies are detailed in Appendix Table 7.  Transfections were 
carried out in 6-well plates according to our previous studies [6].  For co-transfection studies, 50 
pmol or [25 nM] of mimic and 0.5 µg DNA (CMV-EV and CMV-MSI2) were transfected into 
cells using 5 µl of Lipofectamine 2000.  Control co-transfection experiments were first 
performed using a Cy3-labeled negative control mimic and CMV-EV DNA to track the 
transfection of efficiency and to optimize the transfection conditions.    
 
Western Blot Analysis 
Cell lysates were collected 72 hours after transfections using RIPA lysis buffer (50 mM Tris-HCl 
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pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 25x protease 
inhibitor cocktail (Sigma-Alrich) and 1mM PMSF). Protein concentration was determined using 
the Bradford protein assay (Bio-Rad). Proteins were prepared using 6x loading dye (0.375 M 
Tris-HCl, pH 6.8, 12% SDS, 30% β-mercaptoethanol, 60% glycerol, 0.012% bromophenol blue) 
at a concentration of 0.5 – 2 ug/ul, and degraded at 95°C for 10 minutes. Proteins were 
electrophoresed using 10-12% tris-glycine gels and transferred onto PVDF membranes. 
Membranes were blocked in Odyssey® blocking buffer (LI-COR) for 1 hour and then probed 
with primary antibodies overnight. The following primary antibodies were used for our studies; 
anti-Musashi-2, 1:1000 (AbCam #ab76148), anti-Musashi-1 1:1000 (Millipore, 04-1041), β-actin 
1:5000 (Sigma #A5316). Membranes were washed using PBST and probed for 1 hour using anti-
mouse, IRDye® 680RD and anti-rabbit, IRDye® 800CW secondary antibodies (LI-COR) 
protected from light. Membranes were imaged using an Odyssey® Fc dual-mode imaging system 
(LI-COR). 
 
Quantitative Real-Time PCR 
RNA from cells was collected using TRIzol® (Invitrogen) and isolated using Direct-zolTM RNA 
isolation kit (Zymo). Total cDNA was synthesized using reverse transcriptase polymerase and 
random hexamers (Applied Biosystems). Expression of mRNA was measured using quantitative 
real-time PCR using gene specific primers and SYBR® master mix (Applied Biosystems, Life 
Technologies). Expression of mRNA was normalized to control GAPDH and set relative to 
appropriate control. The primers used for this study are outlined in the appendix, Table 8. 
MicroRNA TaqMan® Assay (Life Technologies) was used to quantify the expression of mature 
miR-137. The expression of miR-137 was normalized to housekeeping small RNA, RNU48 and 
set relative to appropriate control. The TaqMan primers used for this study are listed in the 
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appendix, Table 7.  The expression of genes were normalized using the equation 2-ΔCt = 2-(Ct 
(housekeeping gene) – Ct (gene of interest)) [19]. 
 
Statistical Analysis 
Unpaired, two-tailed, T-Test was used to test the significance of two unmatched groups.  The 
data represented are the average results from at least three independent experiments and shown 
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In 2012, over 8 million people worldwide died from cancer and nearly 14 million people were 
diagnosed [1]. The estimated direct cost for cancer in the United States in 2011 was nearly 90 
billion dollars. It is imperative that new methods for combating this deadly and expensive 
disease are actively pursued. The RNA-binding protein Musashi-1 presents an emerging new 
target for cancer therapeutics.  
 
Mouse Musashi-1 contains 362 residues and two evolutionarily conserved ribonucleoprotein 
(RNP)-like RNA-binding domains (RBD), RBD1 and RBD2 [2, 3].  Mouse Musashi-1 and 
Human Musashi-1 share 99% amino acid homology.  The RNP-like RNA-binding domain is a 
common motif found in eukaryotes [4].  Both RNA binding domains share similar folds, 
containing 4 anti-parallel β-sheets packed against two α-helices [5].   
 
Miyanori et al., determined that the first RNA binding domain (RBD1) has a higher affinity for  
RNA than RBD2. All of the residues located at the surface of the anti-parallel β-sheet of RBD1 
are positively charged, providing the necessary electrostatic energy to bind to negatively charged 
RNA. The residues located at the surface of the anti-parallel β-sheet of RBD2 are largely neutral 
in charge. Additionally, RBD1 has a flexible backbone, allowing the necessary dynamics to bind 
to RNA, whereas, RBD2 backbone structure is rigid in nature. Using a variety of methods, 
including gel mobility assays, scientist concluded that RBD1 is the major RNA binding domain 
for MSI1, although, the presence of RBD2 increases the binding affinity to RNA [5, 6]. The 
binding affinity of an RNA binding domain to RNA is not governed by protein fold alone, rather 
a combination of electrostatic potential and backbone flexibility, with RBD1 being more fit to 
bind to RNA.   
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The three-dimensional solution structure of mouse Musashi1 (MSI1) RBD1 and RBD2 have 
been determined using nuclear magnetic resonance (NMR) [3, 5].  In vitro selection methods 
were used to determine the RNA binding sequence of mouse MSI1, identified as (G/A)UnAGU 
(n = 1-3) [7].  Multiple studies have shown that phenylalanines are important for the direct 
interaction between the RNA binding domain and target RNA [3, 5].  Substitutions of these 
phenylalanine residues with alanine residues (F63L, F65L, F68L) inhibits the ability of MSI1 
RBD1 to bind to NUMB RNA [7].  Five MSI1 target mRNAs contain this sequence in their 
3ʹUTR: NUMB [7], p21WAF-1 [8], C-MOS [9], DCX [10] and APC [11]. 
 
Ohyama et al., determined the minimal RNA binding sequences of mouse Musashi1 RBD1 and 
RBD2 using NMR-based binding and structural studies [12]. The consensus binding sequence 
for RBD1 is r(GUAG) and for RBD2 is r(UAG). Using NMR, the binding characteristics of 
RBD1:r(GUAG) was revealed.  Specifically, the adenine of target RNA is sandwiched between 
conserved residue F23 and F96. The fourth guanine is stacked on the conserved F65. The first 
guanine is stacked on W29 located within the loop between α1 and β1 [12]. Additionally, NMR 
revealed that this architecture is highly conserved among MSI1 proteins.  
 
A study done by Abreu et al., found that MSI1 target sequences are generally located in hairpin 
structures, suggesting that RNA secondary structure is an important consideration for MSI1 
recognition [13].  Taken together, the ability of Musashi-1 to bind to target RNA is mediated by 
a variety of characteristics, including protein structure, dynamics, electrostatic potential and the 
secondary structure of target RNA. These characteristics provide an important foundation for the 




MSI1 functions as a translational repressor by binding to the 3ʹUTR of target RNA and blocking 
the Poly(A)-binding protein (PABP) interaction with eIF4a, thus inhibiting the formation of the 
80S ribosome complex [14]. Key targets of MSI1 translational inhibition include NUMB, an 
inhibitor of the Notch pathway [15], p21WAF-1 a cyclin-dependent kinase inhibitor [8] and the 
tumor suppressor APC, an inhibitor of Wnt signaling [16]. Both Notch and Wnt signaling are 
crucial for normal and cancer stem cell homeostasis. Because MSI1 stimulates both Notch and 
Wnt signaling and is also over-expressed in a wide variety of cancers, MSI1 inhibition is an 
attractive target for novel cancer therapy.  In a collaborative effort at the University of Kansas, 
our focus is on the development of small molecule inhibitors of MSI1 as a possible novel 
therapeutic approach.   
 
Screening for MSI1-inhibitors  
Our overall goal is to identify novel compounds which can specifically disrupt unique 
MSI1/RNA interactions, thus leading to MSI1 inhibition. Such compounds would be expected to 
compromise the viability of cancer cells that depend on MSI1 and Notch/Wnt signaling for their 
survival (Figure 1).  RBPs such as MSI1 are considered “undruggable” due to the lack of a well-
defined binding pocket for target RNA. In an effort to “drug the undruggable”, a pilot project 
was funded from NIH COBRE Center for Cancer Experimental Therapeutics (CCET) at the 
University of Kansas to set up a fluorescence polarization (FP)-based binding assay for high-
throughput screening (HTS) to find small molecule inhibitors of MSI1.  Hit compounds were 
then validated using surface plasmon resonance (SPR). After validation, the specific binding 
interaction between hit compounds and MSI1-RBD1 was studied using nuclear magnetic 




From our in-house library of compounds, we identified 3 hit compounds; (‒)-gossypol  ((‒)-G), 
gossypolone (Gn) and azaphilones-9 (AZA-9).  To validate our results and to provide a better 
understanding of the binding event between our hit compounds and MSI1-RBD1, we used NMR 
to characterize the compounds binding activity with MSI1-RBD1.  The NMR characterization of 
the binding interaction of MSI1-RBD1 with lead compounds (‒)-G, Gn, and AZA-9 will be 
described in detail in this chapter.  
 
Figure 1: Project Working Model  
Working model: (Left) In cells with MSI1 overexpression, MSI1 blocks the translation of 
NUMB, p21 and APC mRNA, which leads to the up-regulation of both Notch /Wnt signaling 
pathway and cell cycle progression. Thus MSI1 indirectly promotes proliferation/survival of the 
cells and inhibits apoptosis; (Right) Designed small molecules (yellow circle) will bind to the 
RBD1 of MSI1, presumably releasing NUMB, APC and P21 mRNA from their translational 
repression. Increased level of Numb and APC protein will block Notch and Wnt signaling 
respectively. Increased P21 will block cell cycle progression. This figure was adapted from our 







Figure 2.  Screening Workflow.  
Compounds that inhibit the RNA binding activity of MSI1 are identified using a FP-based 
competition assay.  Hit compounds are then validated using ALPHA and SPR assays. The 
binding and structural characteristics of MSI1-RBD1 bound to lead compounds are then studied 
using a variety of techniques, including NMR, X-ray crystallography and molecular modeling.  
The information collected is used for structure-based rational design of new analogs to improve 

























NMR validation of (‒)-gossypol binding to MSI1:   
(The following results were recently published in Molecular Oncology and reformatted for this 
dissertation [17].)  
 
To confirm the binding of (‒)-gossypol to Msi1 and to determine if this binding event affects the 
RNA binding residues, we employed an NMR assay.  First, we reproduced the previously 
published spectra data for 15N-Msi1-RBD1 bound to a synthetic RNA corresponding to the MSI1 
consensus target site (GUAGU) with consistent results, as shown in Figure 3A left panel [5].  We 
identified known RNA binding residues W29, K93, F23 and F65 Figure 3A right panel, 
consistent with published peak assignments of MSI1 [18].  Specifically, residue F65 is required 
for Msi1-RBD1 to bind to target RNA [7].  In response to increasing doses of (‒)-gossypol, 
residues W29, K93, F23 and F65 peaks exhibited line-broadening, as shown in Figure 3B left 
panel, suggesting that the compound bound most closely to these residues.  Thus (‒)-gossypol 
interacts with the same binding pocket that Msi1 uses to bind target RNA.  In silico docking 
analysis confirms a feasible binding mode for (‒)-gossypol in the lower portion of the RBD1 
binding pocket, with aromatic stacking interactions that mimic the cognate RNA and include 
three of the four shifted residues (F23, K93, F65; Figure 3B right panel).  Based on the NMR 
line-broadening of the remote position W29, (‒)-gossypol (Figure 3B) may also bind to more 




Figure 3. Validation of (‒)-gossypol binding to RBD1 of MSI1 A. (left) Overlay of 2D-HSQC 
spectra sections of 15N-MSI1-RBD1 (black) titrated with RNA oligo (GUAGU). Four of the 
MSI1-RBD1 RNA binding residues were identified (highlighted in box) and undergo significant 
line broadening and peak shifts upon addition of RNA. (right) The structure of RBD1 of MSI1 
bound with RNA (PDB 2RS2). The protein atoms are show as spheres. The RNA is shown as 
sticks. Four of the MSI1-RBD1 RNA binding residues (F23, W29, F65, K93) that undergo 
significant shifts as shown in 2B were highlighted in yellow color. B. (left) Overlay of 2D-
HSQC spectra sections of 15N-MSI1-RBD1 (black) titrated with (‒)-gossypol. RNA binding 
residues (highlighted in box) undergo significant line broadening upon addition of (‒)-gossypol 
indicating micro molar affinity between (‒)-gossypol and RBD1.  The residues that undergo line 
broadening in RBD1 indicates either they are directly involved in binding or they are in close 
proximity of the binding site. (right) The model of RBD1 of MSI1 bound with (‒)-gossypol. The 
protein atoms are colored as described in 2C and the (‒)-gossypol structure was shown as sticks. 






NMR validation of gossypolone binding to MSI1:  
(Unpublished data) 
 
Gossypolone (Gn) is a major metabolite of gossypol [19], and is oxidized in the liver by the P450 
enzyme [20].  It has been shown to share similar biological activity of gossypol [21-27], 
including binding to and inhibiting BCL-2 family member BCL-xL protein, with a Ki of 0.28 
μM [24].  Gn was identified as a potent inhibitor of MSI1s RNA binding activity with a Ki of 
13.5 nM.  The binding activity of Gn to MSI1-RBD1 was confirmed using NMR.  A decrease in 
peak intestity of RNA binding residues K93, F23, W29 and W29ε1 (side chain) with increasing 
titration of Gn suggests that these residues are involved in the binding to Gn (Figure 4).  The 
majority of non-RNA  binding residues were unaffected when titrated with Gn, suggesting that 












Figure 4. Validation of Gn binding to RBD1 of MSI1.  Overlay of 2D-HSQC spectra sections of 
15N-MSI1-RBD1 (black) titrated with Gn.  Three RNA binding residues (highlighted in box) 
undergo line broadening upon addition of Gn indicating that they are in close proximity of the 






NMR validation of AZA-9 binding to MSI1:  
(Unpublished data)  
 
Within our in-house library of compounds was a collection of secondary metabolite analogues 
produced by Aspergillus nidulans [28].  Surprisingly, we found that one particular metabolite, 
AZA-9 showed potent binding affinity to MSI1-RBD1 in FP binding assays with a Ki of 1.18 
µM.  To investigate the mechanism of Aza-9 binding to MSI1-RBD1, we carried out NMR 
studies.  Upon addition of AZA-9 compound, MSI1-RBD1 residues W29, F23, R61, F65, K93 
and M22 experienced significant line broadening at the 1:4 titration, indicating a binding event 
(Figure 5A). When mapped onto the structure of MSI1-RBD1, many of the residues known to 
bind to RNA (W29, F23, F65 and K93) are directly manipulated upon AZA-9 addition, along 
with RNA-binding neighboring residues (M22 and R61) (Figure 5B). The NMR studies confirm 
that AZA-9 directly binds to MSI1-RBD1 and that this binding event affects the RNA binding 




















Figure 5.  (A) Overlay of 2D-HSQC spectra of 15N-MSI1-RBD1 titrated with increasing molar 
ratios of AZA-9.  RNA binding residues W29, F23 and K93 undergo significant line broadening 
upon addition of AZA-9 indicating micro molar binding affinity.  (B)  Structure of RBD1 bound 
to NUMB RNA with RNA binding residues highlighted in yellow. (C) Structure of RBD1 bound 
to NUMB RNA with RNA binding residues affected by AZA-9 titration highlighted in red.   
  
B C 
Bound to RNA Bound to Aza-9 




RNA binding proteins are considered “undruggable”, due to lack of a well-defined binding 
pocket for target RNA. There are a couple of reasons that RNA binding proteins are difficult to 
drug. Unlike many enzymes that have a defined pocket employing the “lock and key” scheme, 
regulatory RNA/DNA binding proteins have shallow binding pockets, and the binding events are 
not tight and less specific.  Targeting protein-protein interaction has yielded a list of small 
molecule compounds that are in clinical trials or in the clinic [29], while inhibitors of protein-
RNA/DNA interaction are fairly new to the arena.   
 
Multiple studies have characterized the binding event between MSI1-RBD1 and target RNA.  
Using site-directed mutagenesis, three phenylalanine residues were substituted for alanine 
residues within MSI1 RBD1 (F63L, F65L, F68L) and shown to inhibit the ability to bind to 
NUMB RNA [7]. In a separate study, researchers used NMR to identify the residues responsible 
for binding to RNA as F23, W29, F65, K93 and F96 [12].  Collectively, these data suggest that 
specifically F65 is required for RNA binding.  In order to inhibit the function of MSI1 RNA 
binding activity, we aimed to identify small molecules that bind to MSI1 and interfere with these 
essential RNA binding residues.   
 
In previous studies, our lab identified three hit compounds that potently inhibit the RNA binding 
activity of MSI1 using FP-based HTS, (‒)-gossypol, Gn, and AZA-9. We used NMR assays to 
study the specific interaction between hit compounds and MSI1-RBD1.  Our study is the first to 
identify small molecule inhibitors of the RNA binding protein Musashi-1 and provide structural 
evidence of binding.  
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 (‒)-Gossypol has completed Phase a IIb multicenter clinical trial for treating prostate cancer 
(e.g., NCT00286806, NCT00286793, NCT00666666) and a variety of other cancers (e.g., 
CT00275431, NCT00397293). These clinical trials stemmed from previous work including 
studies from our lab, which showed that (‒)-gossypol induces autophagy and apoptosis in 
prostate and other cancer cell lines [23, 25, 30]. (‒)-Gossypol has been shown to bind to BCL-2 
family proteins and inhibit their anti-apoptotic and/or anti-autophagic function in various cancer 
cells and to inhibit tumor growth in vivo [30-33].  (‒)-Gossypol binds MSI1 with similar affinity 
as it binds BCL-2 family members, raising the possibility that the drug may also have utility in 
the treatment of cancers associated with high levels of MSI1 expression and Notch/Wnt 
signaling [17]. Repurposing of an existing promising compound such as (‒)-gossypol will 
provide a novel mechanism of action for the compound, and it will also guide the design of new 
clinical trials with new criteria for selecting patient populations that will benefit the most from 
the drug.   
 
Our NMR studies indicate that (‒)-gossypol may compete with target RNAs for binding to MSI1 
by directly interfering with the RNA binding pocket. The observed shift at W29 in the upper 
portion of the binding pocket could be due to a second, cryptic (‒)-gossypol binding site or an 
allosteric effect of binding to the lower portion of the pocket. More biochemical studies and/or 
X-ray crystallography need to be carried out to distinguish between these possibilities.  
 
In terms of target specificity, (‒)-gossypol appears to be a promiscuous compound. Although the 
NMR results showed that (‒)-gossypol affects the known RNA-binding residues; multiple 
residues were also affected outside of the binding pocket. Our results indicate that (‒)-gossypol 
may bind to multiple regions of MSI1-RBD1 or through allosteric interactions affect the overall 
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protein confirmation. Additionally, (‒)-Gossypol has already been shown to be a potent BCL-2 
family protein inhibitor.  In order to move this compound forward as a specific MSI1 inhibitor, 
more detailed structural characteristics using X-ray crystallography to determine the structure of 
(‒)-G and MSI1-RBD1 is critical in order to design (‒)-G derivatives with the hope of improving 
potency and target specificity.  
 
One derivative of (‒)-G that was identified as a hit from our screening pursuits was Gn. Gn had a 
higher binding affinity to MSI1-RBD1 than (‒)-G with a Ki of 13 nM (unpublished data) [17]. 
After titration with Gn, a small collection of residues experienced shifts and/or loss of intensity, 
including RNA binding residues W29, F23 and K93, suggesting that the binding event between 
Gn and MSI1-RBD1 is more localized as compared to the binding event between (‒)-Gossypol 
and MSI1-RBD1.  Future crystallography studies would greatly enhance our knowledge of the 
specific binding event between RBD1 and hit compounds.   
 
In colon cancer cells, the same concentration of Gn is less potent than that of (–)-gossypol in all 
of the assays tested [17].  Gn, a reduced and oxidized form of gossypol, has poor water-solubility 
that can result in compromised cell permeability.  In future studies, the Gn will be delivered to 
cells using a formulated lipid-based nanocarrier.  Liposomes have long been used as nanocarriers 
for targeted cancer therapy and have shown good biocompatibility and controlled drug release in 
some previous studies [34-37].  
 
Surprisingly, we found that one particular secondary metabolite analogue (AZA-9) produced by 
the fungus, Aspergillus nidulans, potently inhibits the RNA binding function of MSI1 
(unpublished data) [28].  We further validated the binding event between AZA-9 and RBD1 
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using NMR.  Our results show that Aza-9 directly binds MSI1 and specifically interferes with 
RNA binding residues W29, F23, F65 and K93 and neighboring residues of the RNA binding 
pocket, M22 and R61. Altogether, it appears that the RNA binding β-sheet of RBD1 is greatly 
affected by AZA-9, indicating that this compound has a great deal of potential in the 
development of an inhibitor of MSI1.  
 
In summary, we discovered three small molecules capable of binding to MSI1-RBD1 and 
manipulating the RNA binding residues.  Our research suggests that RNA binding proteins are 
druggable even though they tend to lack a well-defined binding pocket.  Our study also provides 
substantial evidence that fungus metabolites should be considered more for drug discovery 
studies.  Future studies will focus on characterizing additional hit compounds along with 







Materials and Methods 
 
Protein expression and purification 
Protein used for these studies were produced and purified by the University of Kansas Protein 
Production Group.  pGEX4T-1-MSI1 and pET21a-GB1-RBD1 plasmids encoding full length 
MSI1 and the RNA binding domain 1 (RBD1) of MSI1, were constructed with Mus musculus 
cDNAs under Tac and T7 promoter, respectively.  GB1-RBD1 proteins were expressed in E. coli 
and purified as previously described [38, 39].  Protein concentrations were determined using the 
Bradford assay (Bio-Rad).  
 
Nuclear Magnetic Resonance 
The oligonucleotide sequence for MSI1 RNA binding studies was 5'-GUAGU-3', corresponding 
to MSI1 minimal recognition and binding sequence as previously described [15].  For NMR 
analyses, 15N-labeled GB1-RBD1 protein (residues 20-103) was produced as previously 
described [40].  The 15N-labeled GB1-RBD1 was prepared at the concentration of 200 μM in 
NMR buffer (50mM sodium phosphate pH 7.0, 100 mM NaCl, 10mM β-mercaptoethanol and 
10% D2O).  Labeled 200 µM GB1-RBD1 was titrated with increasing amounts of                (‒)-
gossypol to obtain molar protein:drug ratios of 1:0, 1:0.5, 1:1, and 1:2. Labeled 200 µM GB1-
RBD1 was titrated with increasing amounts of gossypolone to obtain molar protein:drug ratios of 
1:0, 1:0.5, 1:0.75, and 1:1. Labeled 200 µM GB1-RBD1 was titrated with increasing amounts of 
AZA-9 to obtain molar protein:drug ratios of 1:0, 1:0.5, 1:1, 1:2, and 1:4.  
 
2D-1H-15N HSQC spectras were recorded for each titration at 298K on a Bruker Avance 800 
MHz NMR instrument, equipped with a triple resonance (1H/13C/15N) cryoprobe.  NMR 
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backbone assignments for MSI1-RBD1 were obtained from the BMRB (entry 11450). Data was 
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The intricate and sophisticated dance between DNA, RNA and protein is regulated in a tightly 
choreographed fashion, dictating cellular function. Messenger RNAs provide the blueprint for 
protein synthesis and therefore require a great deal of regulation. Two major post-transcriptional 
regulators of the RNA message are RNA-binding proteins (RBPs) and microRNAs (miRNAs). 
The aberrant regulation of miRNAs and RBPs produces a variety of consequences, including the 
initiation and progression of cancer.   
 
One particular miRNA frequently dysregulated in cancer is miR-137.  Silencing of miR-137 can 
be caused by hypermethylation of its promoter region [1, 2].  Low miR-137 due to 
hypermethylation has been identified in colorectal [2], gastric [10], uveal melanoma [12], oral 
cancer [1], glioblastoma multiforme [15], squamous cell carcinoma of head & neck [16, 17], and 
breast cancer [6]. Furthermore, the methylation and silencing of miR-137 occurs early in the 
progression of colorectal cancer [2].   
 
In colon cancer, miR-137 was found to be hypermethylated in 81% of primary tumors (n = 113), 
82% of early adenoma (n = 68) and only 14% of adjacent normal colon mucosa tissue (n = 113).  
Interestingly, miR-137 was hyper-methylated in only 4% of normal colon mucosa tissue (n = 21) 
collected from patients without colorectal cancer.  This data suggests that patients with normal 
methylation status and expression level of miR-137 are less susceptible to developing colorectal 
cancer, but needs to be studied further.  
 
In colon cancer cell lines HCT-116, SW480, and HT29, silencing of miR-137 is due to 
hypermethylation [2].  In our study, we found that MSI1 and MSI2 are overexpressed in these 
cell lines [3].  Additionally, we show that knocking down endogenous miR-137 in multiple cell 
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types, including normal colon cells, increases the mRNA and protein expression of MSI1/MSI2. 
Collectively, the data suggests that hypermethylation and silencing of miR-137 produces an 
overexpression of MSI1/MSI2.  
 
The mechanism responsible for hypermethylation and silencing of miR-137 is not well 
understood.  There is compelling evidence that miR-137 becomes activated during differentiation 
of stem cells in multiple tissue types, but to date, the methylation status of miR-137 in stem cells 
specifically has not been studied. Since tumor initiation and progression has been shown to arise 
from stem-cell like cells, termed cancer stem cells or tumor initiating cells [18], it is possible that 
the hypermethylation status of miR-137 in tumors is due to the expansion of cancer 
stem/progenitor cells with silenced miR-137.   
 
In this body of work, we expand upon the current knowledge of miR-137 by showing evidence 
that the tumor suppressive function of miR-137 in colon cancer is in part by negatively 
regulating the RNA-binding protein, Musashi-1 [3]. We also show preliminary evidence that 
miR-137 also negatively regulates Musashi-2.  However future studies are needed to properly 
understand this mechanism.    
 
In the context of the colon epithelium, MSI1 expression is typically restricted to the base of the 
crypt, marking the LGR5+ and BMI+ stem cell populations [19].  MSI2 is expressed in the base 
of the crypt and transit amplifying region, but not in differentiated intestinal cells [20]. The 
interaction and relevance of miR-137 mediated regulation of MSI1/MSI2 in normal intestinal 
physiology is not understood. One study found that miR-137 is located in the transit amplifying 
region and base of the crypts in normal colonic mucosa using in situ hybridization [2], but it is 
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not clear if miR-137 is expressed in the stem cell population of the crypts. One possibility is that 
miR-137 negatively regulates the expression of MSI1/MSI2 during differentiation of the 
intestinal stem/progenitor cells.  
 
Multiple studies have found that miR-137 is expressed during differentiation of stem cells from a 
variety of tissue types [15].  In neural stem cells, miR-137 is upregulated during differentiation 
and negatively regulates LSD1 [14].  In mouse embryonic stem cells, miR-137, miR-100, and 
miR-34a are upregulated during differentiation [13].  Blocking all three miRNAs inhibits the 
ability of embryonic stem cells to differentiate.  Collectively, the preliminary studies provide 
compelling evidence that miR-137 plays an important role in differentiation.  The role of miR-
137 in the differentiation of intestinal stem cells has not been studied, but would be worth 
investigation in the future.  
 
The mRNA expression of MSI1 is also tightly regulated by the RNA binding protein HuR [21].  
Our lab recently discovered that MSI2 is also regulated by HuR (unpublished data).  HuR  is a 
member of the Hu/ELAV embryonic lethal abnormal vision family of proteins [22].  Containing 
three RNA recognition motifs, HuR functions by binding to AU- or U-rich regions within the 
3′UTR of target RNA [23].  MSI1’s 3′UTR contains multiple AU- and U-rich sequences, 
therefore allowing HuR to bind to and stabilize MSI1 mRNA.  HuR increases the rate of MSI1 
turnover from mRNA to protein in glioblastoma [21].   
 
The miR-137 seed sequence within MSI1’s 3′UTR is located in close proximity to four putative 
HuR binding sites; the closest HuR location resides 76 nucleotides from the miR-137 seed 
sequence.  We show that miR-137 negatively regulates MSI1 in multiple colon cancer cell lines; 
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HCT-116, DLD-1, and HT29. HuR protein expression is overexpressed in these same cell lines 
(unpublished data). Therefore, the miR-137-mediated repression of MSI1 seems to trump the 
HuR mediated stabilization of MSI1 mRNA. The interaction between these two post-
transcriptional regulators of MSI1/MSI2 needs to be studied further. One possibility is that 
although HuR is overexpressed in HCT-116, DLD-1, and HT29, its expression tends to be 
largely localized to the nucleus. Therefore, suggesting that the miR-37 mediated regulation of 
MSI1 is possible because HuR does not have access to MSI1 mRNA.  Returning to the context 
of the colon epithelium and normal physiological functions, the regulation of MSI1/MSI2 
mRNA by HuR and miR-137 is largely understudied.   
 
The signaling pathways mediating wound healing and tumorigenesis are extremely similar and 
thought to be interconnected [24, 25].  The expression of MSI1 seems to be connected with a 
wound healing response. During times of injury either by an infection, UV radiation or ethanol 
induced tissue damage, the expression of MSI1 increases [26-28].  MSI1 response to tissue 
damage is likely due to its important role in maintaining the stem cells and proliferation. During 
times of injury, stem cells are busy regenerating and repairing damaged tissue [25].  One 
possibility is that miR-137 negatively regulates the expression of MSI1 enough to encourage 
differentiation, but during times of stress, the miR-137 mediated regulation of MSI1 is aborted, 
allowing alternative mechanisms, such as HuR, to upregulate MSI1 to promote stem cell 
expansion and tissue regeneration.  Supporting this hypothesis, HuR is enriched in the cytoplasm 
during times of stress [29].  Gaining a better understanding of the miR-137/HuR mediated 
regulation of MSI1/MSI2 in wound healing may help us understand the initiation of 





President Obama recently announced a bold Precision Medicine Initiative in an effort to 
revolutionize health care and biomedical research. With the support of this initiative set to be 
released in 2016, new treatments will be tailored to the specific genomic landscape of an 
individual’s tumor.  Using the advancement in our understanding of basic cancer biology 
coupled with specific therapeutic strategies, physicians can select the most appropriate treatment 
to improve the chances of survival while reducing harsh side effects.  
 
One therapeutic target of interest in our lab is the RNA binding protein and stem cell regulator, 
MSI1.  As previously discussed in detail in Chapter 2, MSI1 is overexpressed in a variety of 
cancers types and associated with poor clinical outcome [3, 30, 31].  Knockdown of MSI1 leads 
to reduced tumor progression in multiple cancer types [32, 33]. Preliminary data suggests that 
inhibition of MSI1 will sensitize cancer to chemo/radio therapy [34] [35].  As an oncogenic 
protein and regulator of stem cell self-renewal, MSI1 makes an attractive target for novel 
molecular therapy targeting cancer stem cells. We investigated two means of therapeutic 
intervention: microRNA-based molecular therapy and designing small molecule inhibitors.  
 
miR-137 based molecular therapy 
Since the tumor suppressor miR-137 has been shown to negatively regulate multiple cancer-
promoting genes, signaling pathways and biological functions (Figure 1), we believe miR-137 is 
an attractive agent for microRNA-based molecular therapy.  MicroRNA-therapeutics is an 
exciting new field within the cancer therapy arena. MicroRNAs make attractive therapeutic 
agents for multiple reasons. First, microRNA-based molecular therapy will utilize a multi-hit 
approach by targeting a subset of genes with oncogenic functions, therefore, enhancing the 
therapeutic effect and hopefully reducing the ability of cancer clones to develop resistance.  
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Additionally, miRNAs are fairly stable in the blood and tissues, enhancing their attraction for 
tumor diagnosis and molecular therapy [36]. 
 
Multiple studies have provided the proof-of-principle that microRNAs can be used as anti-cancer 
therapy, reviewed in [37].  Mirna Therapeutics is sponsoring a first in class clinical trial with 
SMARTICLES® (NCT01829971); a miR-34 liposome based therapeutics. The group recently 
released interim Phase I data describing good safety profiles for patients with liver cancer.     
 
miR-137 has been shown to sensitize neuroblastoma, colon and hepatocellular carcinoma cells to 
doxorubicin by negatively regulating constitutive androstane receptor (CAR), a key player in 
multi-drug resistance (MDR) [7].  In breast cancer cells, miR-137 sensitizes cells to a variety of 
chemotherapy (adriamycin, vincristine, and paclitaxel) by negatively regulating Y-box binding 
protein-1 (YB-1) [38].   
 
In this study, we show that the tumor suppressive function of miR-137 is in part due to 
negatively regulating MSI1 and possibly MSI2.  In colorectal cancer, cells expressing CD133+ 
and MSI1+ are resistant to Oxiliplatin and 5-flurouracil [35, 39].  miR-137 may sensitize cells to 
Oxiliplatin and 5-flurouracil by negatively regulating MSI1.  We are currently conducting 
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Figure 1.  miR-137 negatively regulates multiple tumor promoting genes, signaling pathways 
and biological functions.  
 
MSI1 small molecule inhibitors 
In this work, we provided a comprehensive review of the expression and function of MSI1 and 
MSI2 in a variety of cancer types, along with describing the therapeutic potential of targeting the 
Musashi RNA-binding proteins as novel anti-cancer therapy.  In a highly collaborative effort at 
KU, we identified three hit compounds that bind to and inhibit the RNA binding pocket of MSI1-
RBD1.  In the future, additional hit compounds will be screened and studied for binding affinity 
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and target specificity.  The NMR structure data of hit compounds binding MSI1-RBD1 will be 
used to aid in the development of optimized analogs.  Crystal structures of MSI1-RBD1 bound 
with hit compounds are currently ongoing.   
 
In future studies, a dual MSI1/MSI2 small molecule inhibitor may be considered.  The Musashi 
family of RNA binding proteins is characterized by two RNA recognition motifs (RRMs) [40, 
41].  Structurally, the MSI1 and MSI2 full-length proteins share 69% amino acid homology 
(Figure 2A). MSI1 and MSI2 RRM1 shares 81% amino acid homology and 93% homology in 
RRM2.  The known RNA binding residues (red diamonds in Figure 2a) are perfectly conserved 
in MSI1 and MSI2 RRM1.  The NMR solution structure of MSI1-RBD1 is shown in Figure 2B 
(left model), however the solution structure of MSI2 RBD1 has not been solved.  A model of 
MSI2-RBD1 was predicted using the I-TASSER protein structure prediction program (Figure 
2B, right model) [42]. Although the structure of MSI2-RBD1 needs to be experimentally 
determined by NMR or crystallography, the predicted structure of MSI2-RBD1 is similar to 



















Figure 2: Characterization of MSI1 and MSI2 RNA Binding Domains.  
A) Cartoon visual of MSI1/2 RNA recognition motifs. Red diamonds highlight identified RNA-
binding residues. B) Conserved RNA-binding residues are highlighted in yellow. Target Numb 











The RNA-binding specificity of MSI1 and MSI2 are similar [43] and both have been shown to 
bind to and negatively regulate mNUMB [44, 45].  Since the RNA binding proteins MSI1 and 
MSI2 have been shown to work in redundant manners, it is possible that they compensate for one 
another if one becomes dysregulated or inhibited.  Double knock-in and knock-out studies of 
MSI1 and MSI2 in the colon epithelium and other tissues would greatly enhance our current 
understanding in this regard.  In neurons, a double knock-out of MSI1/MSI2 greatly inhibited 
neurosphere formation, whereas, a single knockout did not [46]. In order to understand the dual 
function of MSI1/MSI2 on tumor growth, we aim to generate a double MSI1/MSI2 knockout cell 
line either by stable transduction or transient transfections. We hope to gain a better 
understanding of how these conserved Musashi proteins work together to promote stem cell 
maintenance and tumorigenesis.  
 
Conclusion  
Musashi RNA binding proteins are critical regulators of stem cell fate and tumorigenesis.  When 
overexpressed in cells, they promote cell proliferation and clonogenic growth by upregulating 
Wnt and Notch signaling pathways and cell cycle progression.  By understanding the regulation 
of MSI1 and its function in cancer, we aimed to develop therapeutic strategies targeting MSI1.  
One goal of this study was to discover if MSI1 was regulated by miRNAs and if this mechanism 
could be exploited as a therapeutic strategy.  In this dissertation, we identified miR-137 as a 
tumor suppressive microRNA in part by negatively regulating MSI1 and possibly MSI2.  We 
provide compelling evidence that miR-137 is an attractive agent for miRNA-based molecular 




In a collaborative effort, we identified hit compounds that inhibit the RNA binding activity of 
MSI1. In this study, we characterized the specific binding event between hit compounds and 
MSI1-RBD1 using NMR.  The results from our studies will be used to design more potent and 
specific inhibitors of MSI1.  Overall, we hope to provide a therapeutic option for patients with 
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Table 1: Alignment of Predicted miRNAs in MSI1 3′UTR 
miRNA Sequence Alignment 
miR-125b 
(1090-1097) 
5′ ...GAAAGCAAAGGGCGUCUCAGGGA...   Msi1 3′UTR 
                      |||||||                                      
3'     AGUGUUCAAUCCCAGAGUCCCU      miR-125b 
miR-137 
(1415-1422) 
5' ...GCCCUGAGAACACAAAGCAAUAA...   Msi1 3′UTR 
                     |||||||  
3'    GAUGCGCAUAAGAAUUCGUUAUU      miR-137 
miR-144 
(779-785) 
5' ...CCCCUCAGACACCGUUACUGUAA...   Msi1 3′UTR 
                     ||||||   
3'      UCAUGUAGUAGAUAUGACAU       miR-144 
miR-342-3p 
(1378-1384) 
5' ...GAGAGUUAAUUGUCUGUGUGAGG...   Msi1 3′UTR 
                     |||||||  
3'    UGCCCACGCUAAAGACACACUCU      miR-342-3p 
miR-185  
(943-949) 
5' ...CUGGACAGGAAUUAACUCUCCAA...   Msi1 3′UTR 
                     ||||||   
3'    AGUCCUUGACGGAAAGAGAGGU       miR-185 
miR-185  
(1722-1729) 
5' ...UCCUCCGGUGUCUCUUCUCUCCA...   Msi1 3′UTR 
                     |||||||  




























Table 2.  Patient and Tumor Characteristics 
Characteristics Msi1 TMA (%) P-value a miR-137 (%) P-value a 
Sex      




   Female 59 (40) 33 (35) 
Age      




   > 70 57 (39) 36 (39) 
TNM      




   II 41 (28) 24 (26) 
   III 54 (37) 32 (34) 
   IV 9 (6) 7 (8) 
Growth Pattern      




   Infiltrative  40 (31) 29 (35) 
Differentiation      
   Good 3 (2) 
0.39 
2 (2) 
0.72    Med 113 (77) 70 (75) 
   Poor (poor + mu + sig) 30 (21) 21 (23) 
Local-Recurrence      




   Yes 22 (15) 17 (18) 
Distant-Recurrence      




   Yes 58 (40) 40 (43) 



















Table 3.  Musashi-1 Staining Intensity in Distant Normal, Adjacent Normal, Biopsy, Primary Tumor and 
Metastatic Rectal Cancer Tissue Samples 
 MSI1 Staining Intensitya 
Tissue Type - + ++ +++ Total N 
Normal 22 (18.6%) 65 (55%) 30 (25.4%) 1 (0.8%) 118 
Adjacent Normal 8 (10%) 32 (40%) 34 (42.5%) 6 (7.5%) 80 
Primary 0 3 (2%) 28 (19%) 115 (78.7%) 146 
Met 0 9 (28.6%) 14 (28.6%) 26 (53%) 49 
























Table 4.  Musashi-1 Expression in Distant Normal, Adjacent Normal, Biopsy, Primary Tumor and 
Metastatic Rectal Cancer Tissue Samples (low vs. high) 
 MSI1 Expressiona  
Tissue Type Low High Total N 
Normal 117 (99%) 1 (1%) 118 
Adjacent Normal 74 (92.5%) 6 (7.5%) 80 
Primary 31 (21%) 115 (79%) 146 
Met 23 (47%) 26 (53%) 49 


























Table 5.  miR-137 Expression in Normal Rectal Tissues and Primary Tumor Rectal Tissue Samples 
 miR-137 Expressiona  
Tissue Type No Change Decreased Increased Total N 
Matched Primarya 2 (3%) 57 (84%) 9 (13%) 68 
Unmatched Primaryb 0 22 (73%) 8 (27%) 30 
Total Primaryc  2(2%) 79 (81%) 17 (17%) 98 
a miR-137 expression in primary tumor tissue sample was normalized to RNU6b and set relative to the 
expression of miR-137 in matching normal tissue sample.  
b miR-137 expression in primary tumor tissue sample was normalized to RNU6b and set relative to the 
average expression of miR-137 in unmatched normal tissue samples.  
c Combined change in miR-137 expression in paired and un-paired primary tumor tissues as compared 






















Table 6.  Correlation of miR-137 and Musashi-1 Expression in Primary Rectal Tumor Tissue Samples 
 miR-137 Expressiona   
MSI1 No Change Decreased Increased Total N P-value d 
Lowb 1 (6%) 13 (76%) 3 (18%) 17 0.54 High c 1 (1%) 57 (81%) 12 (17%) 70 
a miR-137 expression in primary tumor tissue sample was normalized to RNU6b and set relative to the 
expression of miR-137 in normal tissue sample.  
b MSI1 TMA scores of 0+1+2.  
c MSI1 TMA scores of 3.  











Table 7. Antibodies and Reagents 
Product Catalog # Supplier Comments 
Antibodies    
   Rabbit anti-Musashi1 5663 Cell Sign. 1:500 
   Rabbit anti-Musashi1 04-1041 Millipore 1:1000 
   Rabbit anti-Musashi2 Ab76149 AbCam 1:1000 
   Mouse anti-GAPDH sc-51905 Santa Cruz 1:500 
   Rabbit anti-mNumb 2756 Cell Sign. 1:500 
   Rabbit anti-p21 sc-397 Santa Cruz 1:500 
   Rabbit anti-Hes1 Ab71559 Abcam 1:500 
   Rabbit c-Myc 5605 Cell Sign. 1:1000 
   Mouse anti-β-actin A5316 Sigma 1:5000 
   Mouse anti-GAPDH Sc-51095 Santa Cruz 1:500 
   Goat anti-mouse, peroxidase conjugated  31430 Fisher 1:8000 
   Goat anti-rabbit, peroxidase conjugated 31460 Fisher 1:8000 
   Goat anti-mouse, IRDye® 680RD 926-68070 LI-COR 1:15000 
   Goat anti-rabbit, IRDye® 800CW 926-32211 LI-COR 1:15000 
   Rabbit anti-Musashi-1 (for IHC) 04-1041 Millipore 1:50 
   Anti-Rabbit, peroxidase conjugated (for IHC) K4010 Dako  
Reagents    
   Hematoxylin S3302 Dako  
   EnVision+ System-HRP (for IHC)  K4010 Dako  
   Doxycycline Hyclate D9891 Sigma  
   SYBR® Select Master Mix 4472908 AB  
   Lipofectamine 2000 11668019 LT  
   TRIzol 15596 LT  
Plasmids    
   pTRIPZ  Dharmacon  
   pCMV6-MSI1-GFP RG215992 Origene  
   pCMV-MSI2 SC123160 Origene  
   CMV-EV-GFP  Origene Modified 
   Renilla control vector E2241 Promega  
   TOP/FOP vectors 21-170/21-169 Millipore  
Mimics/siRNAs/AntagomiRs    
   hsa-miR-125b miRIDIAN mimic C-300595-03 Dharmacon 100 nM 
   hsa-miR-137 miRIDIAN mimic C-300604-07 Dharmacon 100 nM 
   hsa-miR-144 miRIDIAN mimic C-300612-05 Dharmacon 100 nM 
   hsa-miR-342-3p miRIDIAN mimic C-300696-05 Dharmacon 100 nM 
   hsa-miR-185 miRIDIAN mimic C-300636-07 Dharmacon 100 nM 
   NegCtl. #1, miRIDIAN mimic CN-001000-01 Dharmacon 100 nM 
   hsa-miR-137, miRIDIAN Hairpin Inhibitor IH-300604-08-005 Dharmacon 100 nM 
   NegCtl. #1, miRIDIAN Hairpin Inhibitor IN-001005-01 Dharmacon 100 nM 
   Human Msi1 siRNA J-011338-08 Dharmacon 100 nM 
   Non-targeting-siRNA #1 D-001810-01 Dharmacon 100 nM 
Primers    
   Taqman hsa-miR-137 000593 LT  
   Taqman RNU6b 001093 LT  
   Taqman RNU48 001006 LT  
Abbreviations: AB = Applied Biosystems, LT = Life Technologies, IHC = Immunohistochemistry 
Table 8.  Sequences for Oligonucleotide Primers 
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Genes Accession # Sequence (5′-3′) 
Musashi-1 NM_002442 
F:  TTGGCAGACTACGCAGGAAG 
R:  TGGTCCATGAAAGTGACGAAGC 
Musashi-2 NM_138962.2 
F:  CAACGACTCCCAGCACGAC 
R:  GTCAATCGTCTTGGATCTAACTC 
GAPDH NM_002046 
F:  ATGTTCGTCATGGGTGTGAA 
R:  GGTGCTAAGCAGTTGGTGGT 
Hes-1 NM_005524 
F:  CTGGAGAGGCGGCTAAGGTGTTT 
R:  GTGCCGCTGTTGCTGGTGTAGA 
C-Myc NM_002467 
F:  GCCACGTCTCCACACATCAG 
R:  TCTTGGCAGCAGGATAGTCCTT 
Pre-miR-137 MI0000454 (miRbase) 
F:  CGGTGACGGGTATTCTTGGGTGG 


































































Figure S1. Expression of miR-137 in HCT-116 stable clones 
 
(A) Tet-on miR-137 HCT-116 cells were treated with increasing doses of DOX [µg/ml].  Expression of 
mature miR-137 was analyzed using Taqman qRT-PCR, normalized to RNU6b and set relative to the 
expression of miR-137 in CCD-841.  Expression of miR-137 in WI-38 (lung fibroblast) was also included 
in the study.    
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